WO2007031098A1 - Cell-permeable peptide inhibitors of the jnk signal transduction pathway - Google Patents

Cell-permeable peptide inhibitors of the jnk signal transduction pathway Download PDF

Info

Publication number
WO2007031098A1
WO2007031098A1 PCT/EP2005/009782 EP2005009782W WO2007031098A1 WO 2007031098 A1 WO2007031098 A1 WO 2007031098A1 EP 2005009782 W EP2005009782 W EP 2005009782W WO 2007031098 A1 WO2007031098 A1 WO 2007031098A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
inventive
peptide
jnk
jnk inhibitor
Prior art date
Application number
PCT/EP2005/009782
Other languages
English (en)
French (fr)
Inventor
Christophe Bonny
Original Assignee
Xigen S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen S.A. filed Critical Xigen S.A.
Priority to PCT/EP2005/009782 priority Critical patent/WO2007031098A1/en
Priority to EP06792004A priority patent/EP1928903B1/en
Priority to UAA200804223A priority patent/UA98101C2/ru
Priority to SI200631345T priority patent/SI1928903T1/sl
Priority to US12/066,657 priority patent/US8748395B2/en
Priority to JP2008530405A priority patent/JP5386169B2/ja
Priority to PL11003985T priority patent/PL2418217T4/pl
Priority to HUE11003985A priority patent/HUE029132T2/en
Priority to MEP-2016-62A priority patent/ME02426B/me
Priority to ES11003985.6T priority patent/ES2567708T3/es
Priority to DK11003985.6T priority patent/DK2418217T3/en
Priority to CN2006800333412A priority patent/CN101263157B/zh
Priority to EP15002528.6A priority patent/EP3012266A1/en
Priority to BRPI0616824A priority patent/BRPI0616824B8/pt
Priority to ES06792004T priority patent/ES2388076T3/es
Priority to KR1020087006094A priority patent/KR101305533B1/ko
Priority to DK06792004.1T priority patent/DK1928903T3/da
Priority to EP11003985.6A priority patent/EP2418217B1/en
Priority to RS20120310A priority patent/RS52379B/en
Priority to EA200800680A priority patent/EA014330B1/ru
Priority to CA2621337A priority patent/CA2621337C/en
Priority to PCT/EP2006/008882 priority patent/WO2007031280A2/en
Priority to PT06792004T priority patent/PT1928903E/pt
Priority to ZA200800848A priority patent/ZA200800848B/xx
Priority to MEP-2014-123A priority patent/ME02000B/me
Priority to PL06792004T priority patent/PL1928903T3/pl
Priority to SI200632044A priority patent/SI2418217T1/sl
Priority to AU2006291541A priority patent/AU2006291541B2/en
Priority to RS20160222A priority patent/RS54701B1/en
Publication of WO2007031098A1 publication Critical patent/WO2007031098A1/en
Priority to IL189133A priority patent/IL189133A/en
Priority to NO20081664A priority patent/NO342272B1/no
Priority to HK08112945.3A priority patent/HK1118841A1/xx
Priority to JP2012000381A priority patent/JP5727393B2/ja
Priority to HK12104474.3A priority patent/HK1163712A1/zh
Priority to CY20121100593T priority patent/CY1112924T1/el
Priority to HRP20120598TT priority patent/HRP20120598T1/hr
Priority to US14/144,938 priority patent/US9290538B2/en
Priority to JP2014216270A priority patent/JP2015034171A/ja
Priority to IL237984A priority patent/IL237984A0/en
Priority to US15/045,058 priority patent/US20160264630A1/en
Priority to CY20161100290T priority patent/CY1117351T1/el
Priority to HRP20160379TT priority patent/HRP20160379T1/hr
Priority to HK16112196.9A priority patent/HK1223948A1/zh
Priority to US15/628,771 priority patent/US20170320917A1/en
Priority to US16/525,234 priority patent/US20200062805A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16371—Demonstrated in vivo effect

Definitions

  • the present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling.
  • the c-Jun amino terminal kinase GNK is a member of the stress-activated group of mitogen-activated protein (MAP) kinases. These kinases have been implicated in the control of cell growth and differentiation, and, more generally, in the response of cells to environmental stimuli.
  • MAP mitogen-activated protein
  • the JNK signal transduction pathway is activated in response to environmental stress and by the engagement of several classes of cell surface receptors. These receptors can include cytokine receptors, serpentine receptors and receptor tyrosine kinases. In mammalian cells, JNK has been implicated in biological processes such as oncogenic transformation and mediating adaptive responses to environmental stress.
  • JNK has also been associated with modulating immune responses, including maturation and differentiation of immune cells, as well effecting programmed cell death in cells identified for destruction by the immune system. This unique property makes JNK signaling a promising target for developing pharmacological intervention.
  • JNK signaling is particularly implicated in ischemic stroke and Parkinson's disease.
  • One approach in combating disorders strongly related to JNK signaling is the provision of inhibitors of the JNK signaling pathway.
  • Such inhibitors as already known in the prior art particularly include e.g. upstream kinase inhibitors (for example, CEP-1347), small chemical inhibitors of JNK (SP600125 and AS601245), which directly affect kinase activity e.g.
  • the upstream kinase inhibitor CEP-1347 (KT7515) is a semisynthetic inhibitor of the mixed lineage kinase family.
  • CEP-1347 (KT7515) promotes neuronal survival at dosages that inhibit activation of the c-Jun amino-terminal kinases ONKs) in primary embryonic cultures and differentiated PC12 cells after trophic withdrawal and in mice treated with 1 -methyl-4-phenyl tetrahydropyridine. Further, CEP-1347 (KT7515) can promote long term-survival of cultured chick embryonic dorsal root ganglion, sympathetic, ciliary and motor neurons (see e.g. Borasio et al., Neuroreport. 9(7): 1435-1439, May 11 th 1998.).
  • JNK inhibitor SP600125 was found to reduce the levels of c-Jun phosphorylation, to protect dopaminergic neurons from apoptosis, and to partly restore the level of dopamine in MPTP-induced PD in C57BL/6N mice (Wang et al., Neurosci Res. 2004 Feb; 48(2); 195-202). These results furthermore indicate that JNK pathway is the major mediator of the neurotoxic effects of MPTP in vivo and inhibiting JNK activity may represent a new and effective strategy to treat PD.
  • AS601245 inhibits the JNK signalling pathway and promotes cell survival after cerebral ischemia.
  • AS601245 provided significant protection against the delayed loss of hippocampal CA1 neurons in a gerbil model of transient global ischemia. This effect is mediated by JNK inhibition and therefore by c-Jun expression and phosphorylation (see e.g. Carboni et al., J Pharmacol Exp Ther. 2004
  • a third class of inhibitors of the JNK signaling pathway represent peptide inhibitors of the interaction between JNK and its substrates, as mentioned above.
  • a sequence alignment of naturally occurring JNK proteins may be used.
  • these proteins comprise JNK binding domains GBDs) and occur in various insulin binding (IB) proteins, such as IB1 or IB2.
  • IB insulin binding
  • the results of such an exemplary sequence alignment is e.g. a sequence alignment between the JNK binding domains of IB1 [SEQ ID NO: 13], IB2 [SEQ ID NO: 14], c-Jun [SEQ ID NO: 15] and ATF2 [SEQ ID NO: 16] (see e.g. FIGS. 1A-1 C).
  • Such an alignment reveals a partially conserved 8 amino acid sequence (see e.g. FIG.1A).
  • a comparison of the JBDs of IB1 and IB2 further reveals two blocks of seven and three amino acids that are highly conserved between the two sequences.
  • WO 01/27268 discloses small cell permeable fusion peptides, comprising a so-called TAT cell permeation sequence derived from the basic trafficking sequence of the HIV-TAT protein and a minimum 20 amino acid inhibitory sequence of IBI . Both components are covalently linked to each other.
  • Exemplary (and at present the only) inhibitors of the MAPK-JNK signaling pathway disclosed in WO 01/27268 are e.g.
  • L-JNKI1 JNK-inhibitor peptide composed of L amino acids
  • D-JNKI1 the protease resistant D-JNKI1 peptides GNK-inhibitor peptide composed of non-native D amino acids.
  • JNK-inhibitor ONKI JNK-inhibitor ONKI peptides are specific for JNK ONKl, JNK2 and JNK3.
  • the inhibitor sequences in WO 01/27268 e.g. JNKH , rather inhibit the interaction between JNK and its substrate.
  • the fusion peptide is efficiently transported into cells. Due to the novel properties obtained by the trafficking component the fusion peptides are actively transported into cells, where they remain effective until proteolytic degradation.
  • peptides according to VVO 01/27268 are still easily accessible by phosphorylases (kinases). Any amino acid of a peptide serving as a target for kinases and, therefore, may be subjected to phosphorylation, represents an important factor for inactivating such peptides. Therefore, it is a first object of the present invention to provide novel inhibitor sequences for the JNK signaling pathway, which retain the functional properties of the peptides as disclosed in WO 01/27268 but provide enhanced stability towards phosphorylases (kinases).
  • inhibitor sequences according to WO 01/27268 require an expensive recovery and purification step, particularly if prepared in large scale amounts (e.g. for industrial production).
  • JNK inhibitor sequence comprising less than 150 amino acids in length, wherein the JNK inhibitor sequence comprises or consists of at least one amino acid sequence according to SEQ ID NOs: 1, 2, 3 or 4, or a variant, fragment or derivative thereof.
  • the inventive JNK inhibitor sequence binds JNK and/or inhibits the activation of at least one JNK activated transcription factor, e.g. c-Jun or ATF2 (see e.g. SEQ ID NOs: 15 and 16, respectively) or Elkl .
  • JNK inhibitor sequences according to the present invention comprise a total length of less than 150 amino acid residues, preferably a range of 5 to 150 amino acid residues, more preferably 10 to 100 amino acid residues, even more preferably 10 to 75 amino acid residues and most preferably a range of 15 to 50 amino acid residues.
  • the inventive JNK inhibitor sequence preferably contains or consists of at least one amino acid sequence according to SEQ ID NOs: 1 , 2, 3 or 4, or a fragment, derivative or variant thereof. More preferably, the inventive JNK inhibitor sequence may contain 1 , 2, 3, 4 or even more copies of an amino acid sequence according to SEQ ID NOs: 1 , 2, 3 or 4, or a variant, fragment or derivative thereof. If present in more than one copy, these inventive amino acid sequences according to SEQ ID NOs: 1 , 2, 3 or 4, or variants, fragments, or derivatives thereof may be directly linked with each other without any linker sequence or via a linker sequence comprising 1 to 10, preferably 1 to 5 amino acids.
  • Amino acids forming the linker sequence are preferably selected from glycine or proline as amino acid residues. More preferably, these inventive amino acid sequences according to SEQ ID NOs: 1 , 2, 3 or 4, or fragments, variants or derivatives thereof, may be separated by each other by a hinge of two, three or more proline residues.
  • inventive JNK inhibitor sequences as defined above may be composed of L- amino acids, D-amino acids, or a combination of both.
  • inventive JNK inhibitor sequences comprise at least 1 , preferably at least 3, more preferably at least 6 and even more preferably at least 10 D- and/or L-amino acids, wherein the D- and/or L-amino acids may be arranged in the inventive JNK inhibitor sequences in a blockwise, a non-blockwise or in an alternate manner.
  • inventive JNK inhibitor sequences may be exclusively composed of L-amino acids.
  • inventive JNK inhibitor sequences may then comprise or consist of at least one ,,native JNK inhibitor sequence" according to SEQ ID NO: 1 or 3.
  • the term "native” or “native JNK inhibitor sequence(s)” is referred to non-altered inventive JNK inhibitor sequences according to any of SEQ ID NOs: 1 or 3, entirely composed of L-amino acids.
  • the inventive JNK inhibitor sequence may comprise or consist of at least one (native) amino acid sequence NH 2 -X n b -X n a -RPTTLXLXXXXXXQD-X n b -cooH [SEQ ID NO: 3].
  • each X represents an amino acid residue, preferably selected from any (native) amino acid residue.
  • X n a represents one amino acid residue, preferably selected from any amino acid residue except serine or threonine, wherein n is 0 or 1.
  • each X n b may be selected from any amino acid residue, wherein n is 0-5, 5-10, 10-15, 15-20, 20-30 or more, provided that if n is 0 for X n a , X n b must not comprise a serine or threonine at its C-terminus, in order to avoid a serine or threonine at this position.
  • X n b represents a contiguous stretch of peptide residues derived from SEQ ID NO: 1 or 3.
  • the inventive JNK inhibitor sequence further may comprise or consist of at least one (native) amino acid sequence NH 2 -RPKRPTTLNLFPQVPRSQD-COOH [SEQ ID NO: 1 ].
  • X n a and X n b represent either D or L amino acids.
  • inventive JNK inhibitor sequences may be composed in part or exclusively of D-amino acids. More preferably, these inventive JNK inhibitor sequences composed of D-amino acids are non-native D retro-inverso sequences of the above (native) JNK inhibitor sequences.
  • the term "retro-inverso sequences" refers to an isomer of a linear peptide sequence in which the direction of the sequence is reversed and the chirality of each amino acid residue is inverted (see e.g. Jameson et al., Nature, 368,744-746 (1994); Brady et al., Nature, 368,692-693 (1994)).
  • any given L-amino acid sequence or peptide according to the present invention may be converted into an D retro-inverso sequence or peptide by synthesizing a reverse of the sequence or peptide for the corresponding native L-amino acid sequence or peptide.
  • inventive D retro-inverso sequences as defined above have a variety of useful properties. For example, inventive D retro-inverso sequences enter cells as efficiently as L-amino acid sequences according to the present invention, whereas the inventive D retro-inverso sequences are more stable than the corresponding L- amino acid sequences.
  • the inventive JNK inhibitor sequences may comprise or consist of at least one D retro-inverso sequence according to the amino acid sequence NH 2 -X n b - DQXXXXXXLXLTTPR-X n a -X n b -cooH [SEQ ID NO: 4J.
  • X, X n a and X n b are as defined above (preferably, representing D amino acids), wherein X n b preferably represents a contiguous stretch of residues derived from SEQ ID NO: 2 or 4.
  • the inventive JNK inhibitor sequences may comprise or consist of at least one D retro-inverso sequence according to the amino acid sequence NH 2 - DQSRPVQPFLNLTTPRKPR-cooH [SEQ ID NO: 2].
  • inventive JNK inhibitor sequences as disclosed above are presented in Table 1 (SEQ ID NO:s 1-4).
  • Table 1 presents the name of the inventive JNK inhibitor sequences, as well as their sequence identifier number, their length, and amino acid sequence.
  • prior art sequences according to WO 01/27268 SEQ ID NOs: 17-26 are also given for comparative reasons. These prior art sequences are not disclosed herein as inventive JNK inhibitor sequences or inventive chimeric peptides and are therefore explicitly excluded from the scope of the present invention by way of a disclaimer.
  • the inventive JNK inhibitor sequence comprises or consists of at least one variant, fragment and/or derivative of the above defined inventive native or non-native amino acid sequences according to SEQ ID NOs: 1, 2, 3 or 4.
  • these variants, fragments and/or derivatives retain biological activity of the above disclosed inventive native or non-native JNK inhibitor sequences, particularly of native or non-native amino acid sequences according to SEQ ID NOs: 1, 2, 3 or 4, i.e.
  • JNK binding JNK and/or inhibiting the activation of at least one JNK activated transcription factor, e.g. c-Jun, ATF2 or EIkI .
  • Functionality may be tested by various tests, e.g. binding tests of the peptide to its target molecule or by biophysical methods, e.g. spectroscopy, computer modeling, structural analysis, etc..
  • an inventive JNK inhibitor sequence or variants, fragments and/or derivatives thereof may be analyzed by hydrophilicity analysis (see e.g. Hopp and Woods, 1981.
  • Proc Natl Acad Sci USA 78: 3824-3828 that can be utilized to identify the hydrophobic and hydrophilic regions of the peptides, thus aiding in the design of substrates for experimental manipulation, such as in binding experiments, or for antibody synthesis.
  • Secondary structural analysis may also be performed to identify regions of an (inventive) JNK inhibitor sequence or of variants, fragments and/or derivatives thereof that assume specific structural motifs (see e.g. Chou and Fasman, 1974, Biochem 13: 222-223).
  • Manipulation, translation, secondary structure prediction, hydrophilicity and hydrophobicity profiles, open reading frame prediction and plotting, and determination of sequence homologies can be accomplished using computer software programs available in the art.
  • Other methods of structural analysis include, e.g.
  • the inventive JNK inhibitor sequence may comprise or consist of at least one variant of (native or non-native) amino acid sequences according to SEQ ID NOs: 1 , 2, 3 or 4.
  • a "variant of a (native or non-native) amino acid sequence according to SEQ ID NOs: 1, 2, 3 or 4" is preferably a sequence derived from any of the sequences according to SEQ ID NOs: 1 , 2, 3 or 4, wherein the variant comprises amino acid alterations of the amino acid sequences according to SEQ ID NOs: 1, 2, 3 or 4.
  • Such alterations typically comprise 1 to 20, preferably 1 to 10 and more preferably 1 to 5 substitutions, additions and/or deletions of amino acids according to SEQ ID NOs: 1 , 2, 3 or 4, wherein the variant exhibits a sequence identity with any of the sequences according to SEQ ID NOs: 1, 2, 3 or 4 of at least about 30%, 50%, 70%, 80%, 90%, 95%, 98% or even 99%.
  • variants of inventive (native or non-native) amino acid sequences according to SEQ ID NOs: 1, 2, 3 or 4 are obtained by substitution of specific amino acids, such substitutions preferably comprise conservative amino acid substitutions.
  • Conservative amino acid substitutions may include synonymous amino acid residues within a group which have sufficiently similar physicochemical properties, so that a substitution between members of the group will preserve the biological activity of the molecule (see e.g. Grantham, R. (1974), Science 185, 862-864). It is evident to the skilled person that amino acids may also be inserted and/or deleted in the above-defined sequences without altering their function, particularly if the insertions and/or deletions only involve a few amino acids, e.g.
  • inventive variants which lead to additional threonines at amino acid positions which are accessible for a phosphorylase, preferably a kinase, in order to avoid inactivation of the inventive JNK-inhibitor sequence or of the inventive chimeric peptide in vivo ox in vitro.
  • synonymous amino acid residues which are classified into the same groups and are typically exchangeable by conservative amino acid substitutions, are defined in Table 2.
  • a specific form of a variant of SEQ ID NOs: 1 , 2, 3 or 4 according to the invention is a fragment of the inventive (native or non-native) amino acid sequences according to SEQ ID NOs: 1, 2, 3 or 4", which is typically altered by at least one deletion as compared to SEQ ID NOs 1 , 2, 3 or 4.
  • a fragment comprises at least 4 contiguous amino acids of any of SEQ ID NOs: 1 , 2, 3 or 4, a length typically sufficient to allow for specific recognition of an epitope from any of these sequences.
  • the fragment comprises 4 to 18, 4 to 15, or most preferably 4 to 10 contiguous amino acids of any of SEQ ID NOs: 1 , 2, 3 or 4.
  • Deleted amino acids may occur at any position of SEQ ID NOs: 1, 2, 3 or 4, preferably N- or C-terminally.
  • a fragment of the inventive (native or non-native) amino acid sequences according to SEQ ID NOs: 1, 2, 3 or 4 may be defined as a sequence sharing a sequence identity with any of the sequences according to SEQ ID NOs: 1 , 2, 3 or 4 of at least about 30%, 50%, 70%, 80%, 90%, 95%, 98%, or even 99%.
  • inventive JNK inhibitor sequences may further comprise or consist of at least one derivative of (native or non-native) amino acid sequences according to SEQ ID NO:
  • a "derivative of an (native or non-native) amino acid sequence according to SEQ ID NOs: 1 , 2, 3 or 4" is preferably an amino acid sequence derived from any of the sequences according to SEQ ID NOs: 1 , 2, 3 or 4, wherein the derivative comprises at least one modified L- or D-amino acid (forming non-natural amino acid(s)), preferably 1 to 20, more preferably 1 to 10, and even more preferably 1 to 5 modified L- or D-amino acids. Derivatives of variants or fragments also fall under the scope of the present invention.
  • a modified amino acid in this respect may be any amino acid which is altered e.g. by different glycosylation in various organisms, by phosphorylation or by labeling specific amino acids. Such a label is then typically selected from the group of labels comprising:
  • radioactive labels i.e. radioactive phosphorylation or a radioactive label with sulphur, hydrogen, carbon, nitrogen, etc.
  • colored dyes e.g. digoxygenin, etc.
  • fluorescent groups e.g. fluorescein, etc.
  • an amino acid sequence having a sequence "sharing a sequence identity" of at least, for example, 95% to a query amino acid sequence of the present invention is intended to mean that the sequence of the subject amino acid sequence is identical to the query sequence except that the subject amino acid sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence.
  • up to 5% (5 of 100) of the amino acid residues in the subject sequence may be inserted or substituted with another amino acid or deleted.
  • a "% identity" of a first sequence may be determined with respect to a second sequence.
  • these two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment.
  • a % identity may then be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.
  • JNK-inhibitor sequences according to the present invention may be obtained or produced by methods well-known in the art, e.g. by chemical synthesis or by genetic engineering methods as discussed below.
  • a peptide corresponding to a portion of an inventive JNK inhibitor sequence including a desired region of said JNK inhibitor sequence, or that mediates the desired activity in vitro or in vivo may be synthesized by use of a peptide synthesizer.
  • the present invention provides a chimeric peptide including at least one first domain and at least one second domain, wherein the first domain comprises a trafficking sequence, while the second domain comprises an inventive JNK inhibitor sequence as defined above.
  • chimeric peptides according to the present invention have a length of at least 25 amino acid residues, e.g. 25 to 250 amino acid residues, more preferably 25 to 200 amino acid residues, even more preferably 25 to 150 amino acid residues, 25 to 100 and most preferably amino acid 25 to 50 amino acid residues.
  • the inventive chimeric peptide preferably comprises a trafficking sequence, which is typically selected from any sequence of amino acids that directs a peptide (in which it is present) to a desired cellular destination.
  • the trafficking sequence typically directs the peptide across the plasma membrane, e.g. from outside the cell, through the plasma membrane, and into the cytoplasm.
  • the trafficking sequence may direct the peptide to a desired location within the cell, e.g. the nucleus, the ribosome, the endoplasmic reticulum (ER), a lysosome, or peroxisome, by e.g. combining two components (e.g.
  • the trafficking sequence may additionally comprise another component, which is capable of binding a cytoplasmic component or any other component or compartment of the cell (e.g. endoplasmic reticulum, mitochondria, gloom apparatus, lysosomal vesicles). Accordingly, e.g. the trafficking sequence of the first domain and the JNK inhibitor sequence of the second domain may be localized in the cytoplasm or any other compartment of the cell. This allows to determine localization of the chimeric peptide in the cell upon uptake.
  • the trafficking sequence (being included in the first domain of the inventive chimeric peptide) has a length of 5 to 150 amino acid sequences, more preferably a length of 5 to 100 and most preferably a length of from 5 to 50, 5 to 30 or even 5 to 15 amino acids.
  • the trafficking sequence (contained in the first domain of the inventive chimeric peptide) may occur as a continuous amino acid sequence stretch in the first domain.
  • the trafficking sequence in the first domain may be splitted into two or more fragments, wherein all of these fragments resemble the entire trafficking sequence and may be separated from each other by 1 to 10, preferably 1 to 5 amino acids, provided that the trafficking sequence as such retains its carrier properties as disclosed above.
  • These amino acids separating the fragments of the trafficking sequence may e.g. be selected from amino acid sequences differing from the trafficking sequence.
  • the first domain may contain a trafficking sequence composed of more than one component, each component with its own function for the transport of the cargo JNK inhibitor sequence of the second domain to e.g. a specific cell compartment.
  • the trafficking sequence as defined above may be composed of L-amino acids, D- amino acids, or a combination of both.
  • the inventive trafficking sequences comprise at least 1 , preferably at least 3, more preferably at least 6 and even more preferably at least 10 L-amino acids and/or D-amino acids, wherein the D- and/or L-amino acids may be arranged in the inventive JNK trafficking sequences in a blockwise, a non-blockwise or in an alternate manner.
  • the trafficking sequence of the inventive chimeric peptide may be exclusively composed of L-amino acids. More preferably, the trafficking sequence of the inventive chimeric peptide comprises or consists of at least one ,,native" trafficking sequence as defined above. In this context, the term "native" is referred to non-altered trafficking sequences, entirely composed of L- amino acids.
  • the trafficking sequence of the inventive chimeric peptide may be exclusively composed of D-amino acids. More preferably, the trafficking sequence of the inventive chimeric peptide may comprise a D retro-inverso peptide of the sequences as presented above.
  • the trafficking sequence of the first domain of the inventive chimeric peptide may be obtained from naturally occurring sources or can be produced by using genetic engineering techniques or chemical synthesis (see e.g. Sambrook, J., Fritsch, E. F., Maniatis, T. (1989) Molecular cloning: A laboratory manual. 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).
  • Sources for the trafficking sequence of the first domain may be employed including, e.g. native proteins such as e.g. the TAT protein (e.g. as described in U.S. patent Nos. 5,804,604 and 5,674,980, each of these references being incorporated herein by reference), VP22 (described in e.g. WO 97/05265; Elliott and O'Hare, Cell 88 : 223-233 (1997)), non-viral proteins (Jackson et al, Proc. Natl. Acad. Sci. USA 89 : 10691 -10695 (1992)), trafficking sequences derived from Antennapedia (e.g. the antennapedia carrier sequence) or from basic peptides, e.g.
  • native proteins such as e.g. the TAT protein (e.g. as described in U.S. patent Nos. 5,804,604 and 5,674,980, each of these references being incorporated herein by reference)
  • VP22 described in
  • peptides having a length of 5 to 15 amino acids, preferably 10 to 12 amino acids and comprising at least 80 %, more preferably 85 % or even 90 % basic amino acids, such as e.g. arginine, lysine and/or histidine.
  • variants, fragments and derivatives of one of the native proteins used as trafficking sequences are disclosed herewith. With regard to variants, fragments and derivatives it is referred to the definition given above for JNK inhibitor sequences. Variants, fragments as well as derivatives are correspondingly defined as set forth above for JNK inhibitor sequences.
  • a variant or fragment or derivative may be defined as a sequence sharing a sequence identity with one of the native proteins used as trafficking sequences as defined above of at least about 30%, 50%, 70%, 80%, 90%, 95%, 98%, or even 99%.
  • the trafficking sequence of the first domain comprises or consists of a sequence derived from the human immunodeficiency virus (HIV)I TAT protein, particularly some or all of the 86 amino acids that make up the TAT protein.
  • HIV human immunodeficiency virus
  • partial sequences of the full-length TAT protein may be used forming a functionally effective fragment of a TAT protein, i.e. a TAT peptide that includes the region that mediates entry and uptake into cells.
  • a functionally effective fragment of the TAT protein can be determined using known techniques (see e.g. Franked et al., Proc. Natl. Acad. Sci, USA 86 : 7397-7401 (1989)).
  • the trafficking sequence in the first domain of the inventive chimeric peptide may be derived from a functionally effective fragment or portion of a TAT protein sequence that comprises less than 86 amino acids, and which exhibits uptake into cells, and optionally the uptake into the cell nucleus. More preferably, partial sequences (fragments) of TAT to be used as carrier to mediate permeation of the chimeric peptide across the cell membrane, are intended to comprise the basic region (amino acids 48 to 57 or 49 to 57) of full- length TAT.
  • the inventive trafficking sequence may comprise or consist of an amino acid sequence containing TAT residues 48-57 or 49 to 57, and most preferably a generic TAT sequence NH 2 -X n b -RKKRRQRRR-X n b -cooH [SEQ ID NO: 7], wherein X n b is as defined above.
  • the inventive trafficking sequence may comprise or consist of a peptide containing e.g. the amino acid sequence NH 2 -GRKKRRQRRR-COOH [SEQ ID NO: 5].
  • inventive trafficking sequence may comprise a D retro-inverso peptide of the sequences as presented above, i.e. the D retro-inverso sequence of the generic TAT sequence having the sequence NH 2 -
  • X n b RRRQRRKKR-X n b -cooH [SE Q iD NO : 8]. Also here, X n b is as defined above
  • the inventive trafficking sequence may comprise the D retro-inverso sequence NH 2 -RRRQRRKKRG-COOH [SEQ ID NO: 6].
  • the inventive trafficking sequence may comprise or consist of variants of the trafficking sequences as defined above.
  • a "variant of a trafficking sequence” is preferably a sequence derived from a trafficking sequence as defined above, wherein the variant comprises a modification, for example, addition, (internal) deletion (leading to fragments) and/or substitution of at least one amino acid present in the trafficking sequence as defined above.
  • Such (a) modification(s) typically comprise(s) 1 to 20, preferably 1 to 10 and more preferably 1 to 5 substitutions, additions and/or deletions of amino acids.
  • the variant preferably exhibits a sequence identity with the trafficking sequence as defined above, more preferably with any of SEQ ID NOs: 5 to 8, of at least about 30%, 50%, 70%, 80%,90%, 95%, 98% or even 99%.
  • variants of the trafficking sequence can be designed to modulate intracellular localization of the inventive chimeric peptide.
  • such variants as defined above are typically designed such that the ability of the trafficking sequence to enter cells is retained (i.e. the uptake of the variant of the trafficking sequence into the cell is substantially similar to that of the native protein used a trafficking sequence).
  • alteration of the basic region thought to be important for nuclear localization see e.g. Dang and Lee, J. Biol. Chem. 264 : 18019-18023 (1989); Hauber et al., J. Virol.
  • any of the above disclosed variants of the inventive trafficking sequences can be produced using techniques typically known to a skilled person (see e.g. Sambrook, J., Fritsch, E. F., Maniatis, T. (1989) Molecular cloning: A laboratory manual. 2nd edition. Cold Spring Harbor Laboratory, Cold Spring Harbor, N. Y.)
  • inventive chimeric peptide typically comprises an inventive JNK inhibitor sequence, selected from any of the inventive JNK inhibitor sequences as defined above, including variants, fragments and/or derivatives of these inventive JNK inhibitor sequences.
  • Both domains, i.e. the first and the second domain,(s) of the inventive chimeric peptide may be linked such as to form a functional unit. Any method for linking the first and second domain(s) as generally known in the art may be applied.
  • the first and the second domain(s) of the inventive chimeric peptide are preferably linked by a covalent bond.
  • a covalent bond as defined herein, may be e.g. a peptide bond, which may be obtained by expressing the inventive chimeric protein as a fusion protein. Fusion proteins, as described herein, can be formed and used in ways analogous to or readily adaptable from standard recombinant DNA techniques, as described below. However, both domains may also be linked via side chains or may be linked by a chemical linker moiety.
  • the first and/or second domains of the inventive chimeric peptide may occur in one or more copies in the inventive chimeric peptide. If both domains are present in a single copy, the first domain may be linked either to the N-terminal or the C- terminal end of the second domain. If present in multiple copies, the first and second domain(s) may be arranged in any possible order. E.g. the first domain can be present in the inventive chimeric peptide in a multiple copy number, e.g. in two, three or more copies, which are preferably arranged in consecutive order. Then, the second domain may be present in a single copy occurring at the N- or C-terminus of the sequence comprising the first domain.
  • first and second domain(s) can take any place in a consecutive arrangement. Exemplary arrangements are shown in the following: e.g. first domain - first domain - first domain - second domain; first domain - first domain - second domain - first domain; first domain - second domain - first domain - first domain; or e.g. second domain - first domain - first domain - first domain. It is well understood for a skilled person that these examples are for illustration purposes only and shall not limit the scope of the invention thereto. Thus, the number of copies and the arrangement may be varied as defined initially.
  • the first and second domain(s) may be directly linked with each other without any linker. Alternatively, they may be linked with each other via a linker sequence comprising 1 to 10, preferably 1 to 5 amino acids. Amino acids forming the linker sequence are preferably selected from glycine or proline as amino acid residues. More preferably, the first and second domain(s) may be separated by each other by a hinge of two, three or more proline residues between the first and second domain(s).
  • inventive chimeric peptide as defined above comprising at least one first and at least one second domain, may be composed of L-amino acids, D-amino acids, or a combination of both.
  • each domain (as well as the linkers used) may be composed of L-amino acids, D-amino acids, or a combination of both (e.g. D-TAT and L-IBI (s) or L-TAT and D-IB1 (s), etc.).
  • the inventive chimeric peptide comprises at least 1 , preferably at least 3, more preferably at least 6 and even more preferably at least 10 L-amino acids and/or D-amino acids, wherein the D- and/or L- amino acids may be arranged in the inventive chimeric peptide in a blockwise, a non-blockwise or in an alternate mariner.
  • the inventive chimeric peptide comprises or consists of the L-amino acid chimeric peptides according to the generic L-TAT-IB peptide [NH 2 -X n b -RKKRRQRRR-X n b -X n a -RPTTLXLXXXXXXQD-X n b -cooH, SEQ ID NO: 10], wherein X, X n a and X n b are preferably as defined above.
  • the inventive chimeric peptide comprises or consists of the L-amino acid chimeric peptide L-TAT-IB1 [NH 2 -GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQD-COOH, SEQ ID NO: 9].
  • the inventive chimeric peptide comprises or consists of D-amino acid chimeric peptides of the above disclosed L- amino acid chimeric peptides.
  • Exemplary D retro-inverso chimeric peptides according to the present invention are e.g.
  • the generic D-TAT-IB peptide [NH 2 -X n b - DQXXXXXXLXLTTPR-X ⁇ -X ⁇ RRRQRRKKR-X ⁇ COOH, SEQ ID NO: 12].
  • X, X n a and X n b are preferably as defined above (preferably representing D amino acids). More preferably, the inventive chimeric peptide comprises or consists of D-amino acid chimeric peptides according to the TAT-IB1 peptide [NH 2 - DQSRPVQPFLNLTTPRKPRPPRRRQRRKKRG-coOH, SEQ ID NO: 11 ].
  • the first and second domain(s) of the inventive chimeric peptide as defined above may be linked to each other by chemical or biochemical coupling carried out in any suitable manner known in the art, e.g. by establishing a peptide bond between the first and the second domain(s) e.g. by expressing the first and second domain(s) as a fusion protein, or e.g. by crossl inking the first and second domain(s) of the inventive chimeric peptide.
  • One way to increasing coupling specificity is a direct chemical coupling to a functional group present only once or a few times in one or both of the first and second domain(s) to be crosslinked.
  • cysteine which is the only protein amino acid containing a thiol group, occurs in many proteins only a few times.
  • a crosslinking reagent specific for primary amines will be selective for the amino terminus of that polypeptide.
  • Successful utilization of this approach to increase coupling specificity requires that the polypeptide have the suitably rare and reactive residues in areas of the molecule that may be altered without loss of the molecule's biological activity.
  • Cysteine residues may be replaced when they occur in parts of a polypeptide sequence where their participation in a crosslinking reaction would otherwise likely interfere with biological activity.
  • cysteine residue When a cysteine residue is replaced, it is typically desirable to minimize resulting changes in polypeptide folding. Changes in polypeptide folding are minimized when the replacement is chemically and sterically similar to cysteine. For these reasons, serine is preferred as a replacement for cysteine.
  • a cysteine residue may be introduced into a polypeptide's amino acid sequence for crosslinking purposes.
  • cysteine residue When a cysteine residue is introduced, introduction at or near the amino or carboxy terminus is preferred. Conventional methods are available for such amino acid sequence modifications, wherein the polypeptide of interest is produced by chemical synthesis or via expression of recombinant DNA.
  • Coupling of the first and second domain(s) can also be accomplished via a coupling or conjugating agent.
  • a coupling or conjugating agent There are several intermolecular crosslinking reagents which can be utilized (see for example, Means and Feeney, CHEMICAL MODIFICATION
  • reagents for example, N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) or N,N'-(1,3- phenylene) bismaleimide (both of which are highly specific for sulfhydryl groups and form irreversible linkages); N, N'-ethylene-bis-(iodoacetamide) or other such reagent having 6 to 11 carbon methylene bridges (which are relatively specific for sulfhydryl groups); and l ,5-difluoro-2,4-dinitrobenzene (which forms irreversible linkages with amino and tyrosine groups).
  • SPDP N-succinimidyl 3-(2-pyridyldithio) propionate
  • N,N'-(1,3- phenylene) bismaleimide both of which are highly specific for sulfhydryl groups and form irreversible linkages
  • crosslinking reagents useful for this purpose include: p,p'-difluoro-m, m'-dinitrodiphenylsulfone which forms irreversible crosslinkages with amino and phenolic groups); dimethyl adipimidate (which is specific for amino groups); phenol-1 ,4 disulfonylchloride (which reacts principally with amino groups); hexamethylenediisocyanate or diisothiocyanate, or azophenyl-p-diisocyanate (which reacts principally with amino groups); glutaraldehyde (which reacts with several different side chains) and disdiazobenzidine (which reacts primarily with tyrosine and histidine).
  • Crosslinking reagents may be homobifunctional, i.e. having two functional groups that undergo the same reaction.
  • a preferred homobifunctional crosslinking reagent is bismaleimidohexane ("BMH").
  • BMH contains two maleimide functional groups, which react specifically with sulfhydryl-containing compounds under mild conditions (pH 6.5-7.7). The two maleimide groups are connected by a hydrocarbon chain. Therefore, BMH is useful for irreversible crosslinking of polypeptides that contain cysteine residues.
  • Crosslinking reagents may also be heterobifunctional.
  • Heterobifunctional crosslinking agents have two different functional groups, for example an amine- reactive group and a thiol-reactive group, that will crosslink two proteins having free amines and thiols, respectively.
  • heterobifunctional crosslinking agents are succinimidyl 4-(N- maleimidomethyl)cyclohexane-1 -carboxylate (“SMCC”), m-maleimidobenzoyl-N- hydroxysuccinimide ester (“MBS”), and succinimide 4-(p-maleimidophenyl)butyrate (“SMPB”), an extended chain analog of MBS.
  • SMCC succinimidyl 4-(N- maleimidomethyl)cyclohexane-1 -carboxylate
  • MBS m-maleimidobenzoyl-N- hydroxysuccinimide ester
  • SMPB succinimide 4-(p-maleimidophenyl)butyrate
  • Crosslinking reagents often have low solubility in water.
  • a hydrophilic moiety such as a sulfonate group, may be added to the crosslinking reagent to improve its water solubility.
  • Sulfo-MBS and Sulfo-SMCC are examples of crosslinking reagents modified for water solubility, which may be used according to the present invention.
  • crosslinking reagents yield a conjugate that is essentially non-cleavable under cellular conditions.
  • some crosslinking reagents contain a covalent bond, such as a disulfide, that is cleavable under cellular conditions.
  • a disulfide such as a disulfide
  • DSP dithiobis(succinimidylpropionate)
  • SPDP N-succinimidyl 3-(2- pyridyldithio)propionate
  • SPDP N-succinimidyl 3-(2- pyridyldithio)propionate
  • the use of a cleavable crosslinking reagent permits the cargo moiety to separate from the transport polypeptide after delivery into the target cell. Direct disulfide linkage may also be useful.
  • crosslinking reagents including the ones discussed above, are commercially available. Detailed instructions for their use are readily available from the commercial suppliers. A general reference on protein crosslinking and conjugate preparation is: Wong, CHEMISTRY OF PROTEIN CONJUGATION AND CROSSLINKING, CRC Press (1991).
  • Chemical crosslinking may include the use of spacer arms.
  • Spacer arms provide intramolecular flexibility or adjust intramolecular distances between conjugated moieties and thereby may help preserve biological activity.
  • a spacer arm may be in the form of a polypeptide moiety that includes spacer amino acids, e.g. proline.
  • a spacer arm may be part of the crosslinking reagent, such as in "long- chain SPDP" (Pierce Chem. Co., Rockford, IL., cat. No. 21651 H).
  • variants, fragments or derivatives of one of the above disclosed chimeric peptides are disclosed herewith. With regard to fragments and variants it is generally referred to the definition given above for JNK inhibitor sequences. Particularly, in the context of the present invention, a "variant of a chimeric peptide" is preferably a sequence derived from any of the sequences according to SEQ ID NOs: 9 to 12, wherein the chimeric variant comprises amino acid alterations of the inventive chimeric peptides according to SEQ ID NOs: 9 to 12.
  • Such alterations typically comprise 1 to 20, preferably 1 to 10 and more preferably 1 to 5 substitutions, additions and/or deletions (leading to fragments) of amino acids according to SEQ ID NOs: 9 to 12, wherein the altered inventive chimeric peptide exhibits a sequence identity with any of the sequences according to SEQ ID NOs: 9, 10, 1 1 or 12 of at least about 30%, 50%, 70%, 80%, or 95%, 98%, or even 99%.
  • these variants retain the biological activity of the first and the second domain as contained in the inventive chimeric peptide, i.e. the trafficking activity of the first domain as disclosed above and the activity of the second domain for binding JNK and/or inhibiting the activation of at least one JNK activated transcription factor.
  • the inventive chimeric peptide also comprises fragments of the afore disclosed inventive chimeric peptides, particularly of the inventive chimeric peptide sequences according to SEQ ID NOs: 9, 10, 1 1 or 12.
  • a "fragment of the inventive chimeric peptide" is preferably a sequence derived any of the sequences according to SEQ ID NOs: 9, 10, 11 or 12, wherein the fragment comprises at least 4 contiguous amino acids of any of SEQ ID NOs: 9, 10, 11 or 12.
  • This fragment preferably comprises a length which is sufficient to allow specific recognition of an epitope from any of these sequences and to transport the sequence into the cells, the nucleus or a further preferred location.
  • the fragment comprises 4 to 18, 4 to 15, or most preferably 4 to 10 contiguous amino acids of any of SEQ ID NOs: 9, 10, 11 or 12.
  • Fragments of the inventive chimeric peptide further may be defined as a sequence sharing a sequence identity with any of the sequences according to SEQ ID NOs: 9, 10, 11 or 12 of at least about 30%, 50%, 70%, 80%, or 95%, 98%, or even 99%.
  • the inventive chimeric peptide also comprises derivatives of the afore disclosed inventive chimeric peptides, particularly of the inventive chimeric peptide sequences according to SEQ ID NOs: 9, 10, 11 or 12.
  • the present invention additionally refers to nucleic acid sequences encoding inventive JNK inhibitor sequences, inventive chimeric peptides, or their fragments, variants or derivatives as defined above.
  • a preferable suitable nucleic acid encoding an inventive JNK inhibitor sequence is chosen from human IBl nucleic acid (GenBank Accession No. (AF074091), rat IBl nucleic acid (GenBank Accession No. AF 108959), or human IB2 (GenBank Accession No AF218778).
  • Nucleic acids encoding the inventive JNK inhibitor sequences or chimeric peptides may be obtained by any method known in the art (e.g. by PCR amplification using synthetic primers hybridizable to the 3'- and 5'-termini of the sequence and/or by cloning from a cDNA or genomic library using an oligonucleotide sequence specific for the given gene sequence).
  • nucleic acid sequences are disclosed herein as well, which hybridize under stringent conditions with the appropriate strand coding for a (native) inventive
  • nucleic acid sequences comprise at least 6 (contiguous) nucleic acids, which have a length sufficient to allow for specific hybridization. More preferably, such nucleic acid sequences comprise 6 to 38, even more preferably 6 to 30, and most preferably 6 to 20 or 6 to 10 (contiguous) nucleic acids.
  • stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions can be selected to be about 5°C lower than the thermal melting point (TM) for the specific sequence at a defined ionic strength and pH. The TM is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, stringent conditions will be those in which the salt concentration is at least about 0.02 molar at pH 7 and the temperature is at least about 60 0 C. As other factors may affect the stringency of hybridization (including, among others, base composition and size of the complementary strands), the presence of organic solvents and the extent of base mismatching, the combination of parameters is more important than the absolute measure of any one.
  • High stringency conditions may comprise the following, e.g. Step 1 : Filters containing DNA are pretreated for 8 hours to overnight at 65°C in buffer composed of 6*SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02%
  • Step 2 Filters are hybridized for
  • Step 3 Filters are washed for 1 hour at 37°C in a solution containing 2*SSC, 0.01% PVP,
  • Step 4 Filters are autoradiographed. Other conditions of high stringency that may be used are well known in the art (see e.g. Ausubel et al., (eds.), 1993,
  • Moderate stringency conditions can include the following: Step 1 : Filters containing DNA are pretreated for 6 hours at 55°C. in a solution containing 6*SSC, 5*Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA. Step 2: Filters are hybridized for 18-20 hours at 55°C in the same solution with 5- 20*10 6 cpm 32 P-labeled probe added. Step 3: Filters are washed at 37°C for 1 hour in a solution containing 2*SSC, 0.1 % SDS, then washed twice for 30 minutes at 60 0 C in a solution containing 1 *SSC and 0.1 % SDS.
  • Step 4 Filters are blotted dry and exposed for autoradiography.
  • Other conditions of moderate stringency that may be used are well-known in the art (see e.g. Ausubel et al., (eds.), 1993, Current Protocols in Molecular Biology, John Wiley and Sons, NY; and Kriegler, 1990, Gene Transfer and Expression, a Laboratory Manual, Stockton Press, NY).
  • low stringency conditions can include: Step 1 : Filters containing DNA are pretreated for 6 hours at 40 0 C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1 % PVP, 0.1 % Ficoll, 1% BSA, and 500 ⁇ g/ml denatured salmon sperm DNA.
  • Step 2 Filters are hybridized for 18-20 hours at 40 0 C in the same solution with the addition of 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 ⁇ g/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 x 106 cpm 32 P-labeled probe.
  • Step 3 Filters are washed for 1.5 hours at 55 C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1 % SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 hours at 60 0 C.
  • Step 4 Filters are blotted dry and exposed for autoradiography.
  • filters are washed for a third time at 65-68°C and reexposed to film.
  • Other conditions of low stringency that may be used are well known in the art (e.g. as employed for cross-species hybridizations). See e.g. Ausubel et al., (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley and Sons, NY; and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.
  • nucleic acid sequences provided by the present invention can be used to express inventive peptides, i.e. an inventive JNK inhibitor sequence or an inventive chimeric peptide for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding (inventive) peptides are preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states).
  • inventive peptides i.e. an inventive JNK inhibitor sequence or an inventive chimeric peptide for analysis, characterization or therapeutic use
  • markers for tissues in which the corresponding (inventive) peptides are preferentially expressed either constitutively or at a particular stage of tissue differentiation or development or in disease states.
  • Other uses for the nucleic acids include, e.g. molecular weight markers in gel electrophoresis-based analysis of nucleic acids.
  • expression vectors are also provided for recombinant expression of one or more inventive JNK inhibitor sequences and/or chimeric peptides as defined above.
  • expression vector is used herein to designate either circular or linear DNA or RNA, which is either double-stranded or single-stranded. It further comprises at least one inventive nucleic acid to be transferred into a host cell or into a unicellular or multicellular host organism.
  • inventive expression vector preferably comprises an inventive nucleic acid encoding the inventive JNK inhibitor sequence or a fragment or a variant thereof, or the inventive chimeric peptide, or a fragment or a variant thereof.
  • an expression vector according to the present invention preferably comprises appropriate elements for supporting expression including various regulatory elements, such as enhancers/promoters from viral, bacterial, plant, mammalian, and other eukaryotic sources that drive expression of the inserted polynucleotide in host cells, such as insulators, boundary elements, LCRs (e.g. described by Blackwood and Kadonaga (1998), Science 281, 61-63) or matrix/scaffold attachment regions (e.g. described by Li, Harju and Peterson, (1999), Trends Genet. 15, 403-408).
  • the regulatory elements are heterologous (i.e. not the native gene promoter).
  • the necessary transcriptional and translational signals may also be supplied by the native promoter for the genes and/or their flanking regions.
  • promoter refers to a region of DNA that functions to control the transcription of one or more inventive nucleic acid sequences, and that is structurally identified by the presence of a binding site for DNA-dependent RNA- polymerase and of other DNA sequences, which interact to regulate promoter function.
  • a functional expression promoting fragment of a promoter is a shortened or truncated promoter sequence retaining the activity as a promoter.
  • Promoter activity may be measured by any assay known in the art (see e.g. Wood, de Wet, Dewji, and DeLuca, (1984), Biochem Biophys. Res. Commun. 124, 592-596; Seliger and McElroy, (1960), Arch. Biochem. Biophys. 88, 136-141 ) or commercially available from Promega ® ).
  • an “enhancer region” as used in the inventive expression vector typically refers to a region of DNA that functions to increase the transcription of one or more genes.
  • the term "enhancer”, as used herein, is a DNA regulatory element that enhances, augments, improves, or ameliorates expression of a gene irrespective of its location and orientation vis-a-vis the gene to be expressed, and may be enhancing, augmenting, improving, or ameliorating expression of more than one promoter.
  • Promoter/enhancer sequences as defined above for the inventive expression vector may utilize plant, animal, insect, or fungus regulatory sequences.
  • promoter/enhancer elements can be used from yeast and other fungi (e.g. the GAL4 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase promoter, the alkaline phosphatase promoter).
  • yeast and other fungi e.g. the GAL4 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase promoter, the alkaline phosphatase promoter.
  • they may include animal transcriptional control regions, e.g. (i) the insulin gene control region active within pancreatic ⁇ -cells (see e.g. Hanahan, et al., 1985.
  • inventive expression vector may comprise an amplification marker.
  • This amplification marker may be selected from the group consisting of, e.g. adenosine deaminase (ADA), dihydrofolate reductase (DHFR), multiple drug resistance gene (MDR), ornithine decarboxylase (ODC) and N-(phosphonacetyl) -L- aspartate resistance (CAD).
  • ADA adenosine deaminase
  • DHFR dihydrofolate reductase
  • MDR multiple drug resistance gene
  • ODC ornithine decarboxylase
  • CAD N-(phosphonacetyl) -L- aspartate resistance
  • Exemplary expression vectors or their derivatives suitable for the present invention particularly include, e.g. human or animal viruses (e.g. vaccinia virus or adenovirus); insect viruses (e.g. baculovirus); yeast vectors; bacteriophage vectors (e.g. lambda phage); plasmid vectors and cosmid vectors.
  • human or animal viruses e.g. vaccinia virus or adenovirus
  • insect viruses e.g. baculovirus
  • yeast vectors e.g. bacteriophage vectors (e.g. lambda phage); plasmid vectors and cosmid vectors.
  • the present invention additionally provides a variety of host-vector systems, which may be utilized to express the peptide coding sequence(s) of inventive nucleic acids as defined above.
  • host-vector systems include, but are not limited to: (i) mammalian cell systems that are infected with vaccinia virus, adenovirus, and the like; (ii) insect cell systems infected with baculovirus and the like; (iii) yeast containing yeast vectors or (iv) bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA.
  • any one of a number of suitable transcription and translation elements may be used.
  • a host cell strain suitable for such a host-vector system, may be selected that modulates the expression of inserted sequences of interest, or modifies or processes expressed peptides encoded by the sequences in the specific manner desired.
  • expression from certain promoters may be enhanced in the presence of certain inducers in a selected host strain; thus facilitating control of the expression of a genetically-engineered peptide.
  • different host cells possess characteristic and specific mechanisms for the translational and post- translational processing and modification (e.g. glycosylation, phosphorylation, and the like) of expressed peptides. Appropriate cell lines or host systems may thus be chosen to ensure the desired modification and processing of the foreign peptide is achieved. For example, peptide expression within a bacterial system can be used to produce an non-glycosylated core peptide; whereas expression within mammalian cells ensures "native" glycosylation of a heterologous peptide.
  • the present invention further provides antibodies directed against the inventive JNK inhibitor sequences and/or inventive chimeric peptides. Furthermore, efficient means for production of antibodies specific for JNK inhibitor sequences according to the present invention, or for inventive chimeric peptides containing such an inhibitor sequence, are provided.
  • JNK inhibitor sequences and/or inventive chimeric peptides may be utilized as immunogens to generate antibodies that immunospecifically bind these peptide components.
  • Such antibodies include, e.g. polyclonal, monoclonal, chimeric, single chain, Fab fragments and a Fab expression library.
  • the present invention provides antibodies to inventive chimeric peptides or to JNK inhibitor sequences as defined above. Various procedures known within the art may be used for the production of these inventive antibodies.
  • various host animals may be immunized for production of polyclonal antibodies' by injection with any inventive chimeric peptide or JNK inhibitor sequence as defined above.
  • Various adjuvants may be used thereby to increase the immunological response which include, but are not limited to, Freund's (complete and incomplete) adjuvant, mineral gels (e.g. aluminum hydroxide), surface active substances (e.g. lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), CpG, polymers, Pluronics, and human adjuvants such as Bacille Calmette-Guerin and Corynebacterium parvum.
  • any technique may be utilized that provides for the production of antibody molecules by continuous cell line culture.
  • Such techniques include, but are not limited to, the hybridoma technique (see Kohler and Milstein, 1975. Nature 256: 495-497); the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983, Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al v 1985. In: Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
  • Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by the use of human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al.,1985. In: Monoclonal Antibodies and Cancer Therapy (Alan R. Liss, Inc., pp. 77-96).
  • techniques can be adapted for the production of single- chain antibodies specific to the inventive JNK inhibitor sequences and/or inventive chimeric peptides (see e.g. U. S. Patent No. 4,946,778).
  • methods can be adapted for the construction of Fab expression libraries (see e.g. Huse et al., 1989. Science 246: 1275-1281 ) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for these inventive JNK inhibitor sequences and/or inventive chimeric peptides as defined above.
  • Non-human antibodies can be "humanized" by techniques well known in the art (see e.g. U. S. Patent No. 5,225,539).
  • Antibody fragments that contain the idiotypes to a JNK inhibitor sequences and/or inventive chimeric peptide may be produced by techniques known in the art including, e.g. (i) a F(ab') 2 fragment produced by pepsin digestion of an antibody molecule; (ii) a Fab fragment generated by reducing the disulfide bridges of an F(ab') 2 fragment ; (iii) a Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) Fv fragments.
  • methods for the screening of inventive antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art.
  • ELISA enzyme-linked immunosorbent assay
  • selection of antibodies that are specific to a particular epitope of an inventive JNK inhibitor sequence and/or an inventive chimeric peptide is facilitated by generation of hybridomas that bind to the fragment of an inventive JNK inhibitor sequence and/or an inventive chimeric peptide possessing such an epitope.
  • ELISA enzyme-linked immunosorbent assay
  • inventive antibodies may be used in methods known within the art referring to the localization and/or quantification of an inventive JNK inhibitor sequence (and/or correspondingly to an inventive chimeric peptide), e.g. for use in measuring levels of the peptide within appropriate physiological samples, for use in diagnostic methods, or for use in imaging the peptide, and the like.
  • compositions can be formulated in pharmaceutical compositions, also encompassed herewith.
  • These compositions may comprise, in addition to one of these substances, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
  • a pharmaceutically acceptable excipient such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
  • the precise nature of the carrier or other material may depend on the route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal or patch routes.
  • Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form.
  • a tablet may include a solid carrier such as gelatin or an adjuvant.
  • Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil.
  • a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil.
  • Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
  • the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
  • a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
  • isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
  • Preservatives, stabilizers, buffers, antioxidants and/or other additives may be included, as required.
  • administration is preferably in a "prophylactically effective amount or a "therapeutically effective amount” (as the case may be), this being sufficient to show benefit to the individual.
  • a proliferatively effective amount or a "therapeutically effective amount” (as the case may be)
  • the actual amount administered, and rate and time-course of administration will depend on the nature and severity of what is being treated.
  • Prescription of treatment is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in REMINGTON'S PHARMACEUTICAL SCIENCES, 16th edition, Osol, A. (ed), 1980.
  • targeting therapies may be used to deliver the inventive JNK inhibitor sequences, chimeric peptides, and nucleic acids of the invention more specifically to certain types of cell, by the use of targeting systems such as (a targeting) antibody or cell specific ligands.
  • targeting systems such as (a targeting) antibody or cell specific ligands.
  • Antibodies used for targeting are typically specific for cell surface proteins of cells associated with any of the diseases as defined below.
  • these antibodies may be directed to cell surface antibodies such as e.g. B cell-associated surface proteins such as MHC class II DR protein, CD18 (LFA- 1 beta chain), CD45RO, CD40 or Bgp95, or cell surface proteins selected from e.g.
  • Targeting constructs may be typically prepared by covalently binding the inventive JNK inhibitor sequences, chimeric peptides, and nucleic acids to an antibody specific for a cell surface protein or by binding to a cell specific ligand. Proteins may e.g. be bound to such an antibody or may be attached thereto by a peptide bond or by chemical coupling, crosslinking, etc..
  • the targeting therapy may then be carried out by administering the targeting construct in a pharmaceutically efficient amount to a patient by any of the administration routes as defined below, e.g. intraperitoneal, nasal, intravenous, oral and patch delivery routes.
  • the inventive JNK inhibitor sequences, chimeric peptides, or nucleic acids of the invention attached to the targeting antibodies or cell specific ligands as defined above may be released in vitro or in vivo, e.g. by hydrolysis of the covalent bond, by peptidases or by any other suitable method.
  • inventive JNK inhibitor sequences, chimeric peptides, or nucleic acids of the invention are attached to a small cell specific ligand, release of the iigand may not be carried out. If present at the cell surface, the inventive chimeric peptides may enter the cell upon the activity of its trafficking sequence. Targeting may be desirable for a variety of reasons; for example if the inventive JNK inhibitor sequences, chimeric peptides, and nucleic acids of the invention are unacceptably toxic or if it would otherwise require a too high dosage.
  • inventive JNK inhibitor sequences and/or chimeric peptides of the invention could be produced in the target cells by expression from an encoding gene introduced into the cells, e.g. from a viral vector to be administered.
  • the viral vector typically encodes the inventive JNK inhibitor sequences and/or chimeric peptides of the invention.
  • the vector could be targeted to the specific cells to be treated.
  • the vector could contain regulatory elements, which are switched on more or less selectively by the target cells upon defined regulation.
  • This technique represents a variant of the VDEPT technique (virus-directed enzyme prodrug therapy), which utilizes mature proteins instead of their precursor forms.
  • inventive JNK inhibitor sequences and/or chimeric peptides could be administered in a precursor form by use of an antibody or a virus.
  • inventive JNK inhibitor sequences and/or chimeric peptides may then be converted into the active form by an activating agent produced in, or targeted to, the cells to be treated.
  • an activating agent produced in, or targeted to, the cells to be treated.
  • This type of approach is sometimes known as ADEPT (antibody-directed enzyme prodrug therapy) or VDEPT (virus-directed enzyme prodrug therapy); the former involving targeting the activating agent to the cells by conjugation to a cell- specific antibody, while the latter involves producing the activating agent, e.g. a JNK inhibitor sequence or the chimeric peptide, in a vector by expression from encoding DNA in a viral vector (see for example, EP-A-415731 and WO 90/07936).
  • the present invention further encompasses the use of inventive JNK inhibitor sequences, inventive chimeric peptides and/or inventive nucleic acid sequences, for preparing a pharmaceutical composition, e.g. as defined above, for preventing and/or treating cell-proliferative disorders associated with JNK activation in a subject ("JNK associated disorder").
  • such a pharmaceutical composition used according to the present invention includes as an active component, e.g.: (i) any one or more of the inventive JNK inhibitor sequences and/or inventive chimeric peptides, and/or variants, fragments or derivatives thereof; and/or (ii) nucleic acids encoding an inventive JNK inhibitor sequence and/or an inventive chimeric peptide and/or variants or fragments thereof, and/or (iii) cells comprising any one or more of the inventive JNK inhibitor sequences and/or inventive chimeric peptides, and/or variants, fragments or derivatives thereof and/or (iv) cells transfected with a vector and/or nucleic acids encoding an inventive JNK inhibitor sequence and/or an inventive chimeric peptide and/or variants or fragments thereof.
  • active component e.g.: (i) any one or more of the inventive JNK inhibitor sequences and/or inventive chimeric peptides, and/or variants, fragments or derivatives thereof; and
  • Prevention and/or treatment according to the present invention typically includes administration of an inventive pharmaceutical composition as defined above.
  • modulate includes the suppression of expression of JNK when it is over- expressed. It also includes suppression of phosphorylation of c-jun, ATF2 or NFAT4, for example, by using a peptide of any one or more of SEQ ID NOs: 1-4 and/or 9-12 as a competitive inhibitor of the natural c-jun, ATF2 and NFAT4 binding site in a cell.
  • modulate also includes suppression of hetero- and homomeric complexes of transcription factors made up of c-jun, ATF2, or NFAT4 and their related partners, such as for example the AP-1 complex that is made up of c-jun, AFT2 and c-fos.
  • suppressive JNK inhibitor sequences can be introduced to a cell.
  • modulate may include the increase of JNK expression, for example by use of an IB peptide-specific antibody that blocks the binding of an IB- peptide to JNK, thus preventing JNK inhibition by the IB-related peptide.
  • Prevention and/or treatment of a subject with the inventive pharmaceutical composition as disclosed above may be typically accomplished by administering (in vivo) an ("therapeutically effective") amount of said pharmaceutical composition to a subject, wherein the subject may be e.g. any mammal, e.g. a human, a primate, mouse, rat, dog, cat, cow, horse or pig.
  • therapeutically effective means that the active component of the pharmaceutical composition is of sufficient quantity to ameliorate the JNK associated disorder.
  • cell-proliferative disorder or "JNK associated disorder” as used above typically denotes malignant as well as non-malignant cell populations in vivo and in vitro that often appear to differ morphologically and functionally from the surrounding tissue and which are typically characterized by aberrant levels of JNK.
  • An "aberrant level of JNK” is intended to mean an increased or decreased level of JNK in a part of the subject to be treated relative to that present in an analogous unaffected part of a subject not having the disorder.
  • inventive pharmaceutical compositions may be useful in preventing, and/or treating malignancies of the various organ systems, in which activation of JNK has often been demonstrated, e.g. lung, breast, lymphoid, gastrointestinal, and genito-urinary tract as well as adenocarcinomas which include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.
  • Leukemia, disorders or pathophysiologies associated with oncogenic transformation as well as cancers with Bcr-Abl oncogenic transformations that clearly require activation of JNK are also included.
  • inventive pharmaceutical compositions are also applicable in preventing and/or treating non-malignant or immunological-related cell proliferative diseases such as psoriasis, pemphigus vulgaris, Behcet's syndrome, acute respiratory distress syndrome (ARDS), ischemic heart disease, post-dialysis syndrome, rheumatoid arthritis, acquired immune deficiency syndrome, vasculitis, septic shock and other types of acute inflammation, and lipid histiocytosis.
  • non-malignant or immunological-related cell proliferative diseases such as psoriasis, pemphigus vulgaris, Behcet's syndrome, acute respiratory distress syndrome (ARDS), ischemic heart disease, post-dialysis syndrome, rheumatoid arthritis, acquired immune deficiency syndrome, vasculitis, septic shock and other types of acute inflammation, and lipid histiocytosis.
  • immunopathological disorders Essentially, any disorder, which is etiologically linked to JNK
  • disorders or pathophysiologies associated with activation of JNK in a cell or cells as defined above e.g. restenosis, hearing loss, ear trauma, ischemia, stroke and/or disorders or pathophysiologies associated with maturation and differentiation of immune cells, reperfusion injuries, hypoxia, apoptosis-related diseases (e.g. occurring in viral infections (e.g. AIDS), autoimmune diseases, neurodegenerative disorders (e.g. stroke, brain trauma, spinal cord injury, amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, and Parkinson's disease), cardiovascular disease, osteoporosis and aging), response to stressful stimuli, and with secondary effects due to treatment with e.g. proinflammatory cytokines.
  • apoptosis-related diseases e.g. occurring in viral infections (e.g. AIDS)
  • autoimmune diseases e.g. stroke, brain trauma, spinal cord injury, amyotrophic lateral sclerosis (ALS), Huntington's disease,
  • the inventive pharmaceutical composition may also be used to treat or prevent effects associated with diabetes or with cellular shear stress, such as in pathological states induced by arterial hypertension, including heart and cardiac hypertrophy and arteriosclerotic lesions, and at bifurcations of blood vessels, and the like, by ionizing radiation, as used in radiotherapy and ultraviolet light (UV lights), by free radicals, DNA damaging agents, including chemotherapeutic drugs, by ischemia/reperfusion injuries, by hypoxia; and/or hypo-and hyperthermia.
  • the inventive pharmaceutical composition may be used to inhibit expression of genes whose expression increases in the presence of an active JNK polypeptide.
  • These genes and gene products typically include e.g. proinflammatory cytokines.
  • proinflammatory cytokines are found in all forms of inflammatory, autoinflammatory, immune and autoimmune diseases, degenerative diseases, myopathies, cardiomyopathies, and graft rejection.
  • inventive JNK inhibitor sequences, inventive chimeric peptides or inventive nucleic acid sequences further may be used in any situation in which inhibition of JNK activity is desired, since JNKs and all its isoforms participate in the development and establishment of pathological states or in pathways thereof. Such use can include in vitro applications, ex vivo, and in vivo applications.
  • inventive nucleic acids as defined above may be utilized in a specific embodiment of the present invention to modulate activated JNK signaling pathways by way of gene therapy, preferably for treating one of the conditions, diseases, and/ or disorders as defined above.
  • gene therapy refers to therapy that is performed by administration of a specific inventive nucleic acid to a subject, e.g. by way of a pharmaceutical composition as defined above, wherein the inventive nucleic acid(s) exclusively comprise(s) L-amino acids.
  • the nucleic acid produces its encoded peptide(s), which then serve(s) to exert a therapeutic effect by modulating function of the disease or disorder.
  • Any of the methods relating to gene therapy available within the art may be used in the practice of the present invention (see e.g. Goldspiel, et al., 1993. Clin Pharm 12: 488-505).
  • the inventive nucleic acid used for gene therapy is part of an expression vector expressing any one or more of the inventive IB-related peptides, i.e. an inventive JNK inhibitor sequence and/or an inventive chimeric peptide, or fragments or derivatives thereof, within a suitable host.
  • an expression vector possesses a promoter that is operably-linked to coding region(s) of a JNK inhibitor sequence.
  • the promoter may be defined as above, e.g. inducible or constitutive, and, optionally, tissue-specific.
  • a inventive nucleic acid molecule is used for gene therapy, in which the coding sequences of the inventive nucleic acid molecule (and any other desired sequences thereof) are flanked by regions that promote homologous recombination at a desired site within the genome, thus providing for intra-chromosomal expression of nucleic acids (see e.g. Koller and Smithies, 1989. Proc Natl Acad Sci USA 86: 8932-8935).
  • nucleic acid for the into a patient purpose of gene therapy may be either direct (i.e. the patient is directly exposed to the nucleic acid or nucleic acid-containing vector) or indirect (i.e. cells are first transformed with the nucleic acid in vitro, then transplanted into the patient). These two approaches are known, respectively, as in vivo or ex ⁇ //Vo gene therapy.
  • a nucleic acid is directly administered in vivo, where it is expressed to produce the encoded product. This may be accomplished by any of numerous methods known in the art including, e.g.
  • nucleic acid as part of an appropriate nucleic acid expression vector and administering the same in a manner such that it becomes intracellular (e.g. by infection using a defective or attenuated retroviral or other viral vector; see U. S. Patent No. 4,980,286); directly injecting naked DNA; using microparticle bombardment (e.g.
  • a "GeneGun” Biolistic, DuPont
  • coating the nucleic acids with lipids using associated cell- surface receptors/transfecting agents; encapsulating in liposomes, microparticles, or microcapsules; administering it in linkage to a peptide that is known to enter the nucleus; or by administering it in linkage to a ligand predisposed to receptor- mediated endocytosis (see e.g. Wu and Wu, 1987.J Biol Chem 262: 4429-4432), which can be used to "target" cell types that specifically express the receptors of interest, etc.
  • An additional approach to gene therapy in the practice of the present invention involves transferring a gene into cells in in vitro tissue culture by such methods as electroporation, lipofection, calcium phosphate-mediated transfection, viral infection, or the like.
  • the method of transfer includes the concomitant transfer of a selectable marker to the cells.
  • the cells are then placed under selection pressure (e.g. antibiotic resistance) so as to facilitate the isolation of those cells that have taken up, and are expressing, the transferred gene.
  • selection pressure e.g. antibiotic resistance
  • Those cells are then delivered to a patient.
  • the nucleic acid is introduced into a cell by any method known within the art including e.g.
  • transfection electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences of interest, cell fusion, chromosome-mediated gene transfer, rnicrocell-mediated gene transfer, spheroplast fusion, and similar methods that ensure that the necessary developmental and physiological functions of the recipient cells are not disrupted by the transfer. See e.g. Loeffler and Behr, 1993. Meth Enzymol 217 : 599-618.
  • the chosen technique should provide for the stable transfer of the nucleic acid to the cell, such that the nucleic acid is expressible by the cell.
  • the transferred nucleic acid is heritable and expressible by the cell progeny.
  • the resulting recombinant cells may be delivered to a patient by various methods known within the art including, e.g. injection of epithelial cells (e.g. subcutaneously), application of recombinant skin cells as a skin graft onto the patient, and intravenous injection of recombinant blood cells (e.g. hematopoietic stem or progenitor cells).
  • epithelial cells e.g. subcutaneously
  • recombinant skin cells as a skin graft onto the patient
  • recombinant blood cells e.g. hematopoietic stem or progenitor cells.
  • the total amount of cells that are envisioned for use depend upon the desired effect, patient state, and the like, and may be determined by one skilled within the art.
  • Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and may be xenogeneic, heterogeneic, syngeneic, or autogeneic.
  • Cell types include, but are not limited to, differentiated cells such as epithelial cells, endothelial cells, keratin ocytes, fibroblasts, muscle cells, hepatocytes and blood cells, or various stem or progenitor cells, in particular embryonic heart muscle cells, liver stem cells (International Patent Publication WO 94/08598), neural stem cells (Stemple and Anderson, 1992,CeII 71 : 973-985), hematopoietic stem or progenitor cells, e.g. as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, and the like.
  • the cells utilized for gene therapy are autologous to the patient.
  • inventive JNK inhibitor sequences, inventive chimeric peptides, inventive nucleic acid sequences or antibodies to inventive JNK inhibitor sequences or to inventive chimeric peptides may be utilized in ⁇ in vitro) assays (e.g. immunoassays) to detect, prognose, diagnose, or monitor various conditions, diseases, and/ or disorders as defined above, or monitor the treatment thereof.
  • the immunoassay may be performed by a method comprising contacting a sample derived from a patient with an antibody to an inventive JNK inhibitor sequence, an inventive chimeric peptide, or an inventive nucleic acid sequence, under conditions such that immunospecific-binding may occur, and subsequently detecting or measuring the amount of any immunospecific-binding by the antibody.
  • an antibody specific for an inventive JNK inhibitor sequence, inventive chimeric peptide or inventive nucleic acid sequence may be used to analyze a tissue or serum sample from a patient for the presence of JNK or a JNK inhibitor sequence; wherein an aberrant level of JNK is indicative of a diseased condition.
  • the immunoassays include, but are not limited to, competitive and non-competitive assay systems using techniques such as Western Blots, radioimmunoassays (RIA), enzyme linked immunosorbent assay (ELISA), "sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, fluorescent immunoassays, complement-fixation assays, immunoradiometric assays, and protein-A immunoassays, etc..
  • ⁇ in vitro) assays may be performed by delivering the inventive JNK inhibitor sequences, inventive chimeric peptides, inventive nucleic acid sequences or antibodies to inventive JNK inhibitor sequences or to inventive chimeric peptides to target cells typically selected from e.g. cultured animal cells, human cells or micro-organisms, and to monitor the cell response by biophysical methods typically known to a skilled person.
  • the target cells typically used therein may be cultured cells (in vitro) or in vivo cells, i.e. cells composing the organs or tissues of living animals or humans, or microorganisms found in living animals or humans.
  • kits for diagnostic or therapeutic use that include one or more containers containing inventive JNK inhibitor sequences, inventive chimeric peptides, inventive nucleic acid sequences and/or antibodies to inventive JNK inhibitor sequences or to inventive chimeric peptides, e.g. an anti-JNK inhibitor sequence antibody and, optionally, a labeled binding partner to the antibody.
  • the label incorporated thereby into the antibody may include, but is not limited to, a chemiluminescent, enzymatic, fluorescent, colorimetric or radioactive moiety.
  • kits for diagnostic use comprise one or more containers containing nucleic acids that encode, or alternatively, that are the complement to, an inventive JNK inhibitor sequence and/or an inventive chimeric peptide, optionally, a labeled binding partner to these nucleic acids, are also provided.
  • the kit may comprise, in one or more containers, a pair of oligonucleotide primers (e.g. each 6- 30 nucleotides in length) that are capable of acting as amplification primers for polymerase chain reaction (PCR; see e.g. lnnis, et al., 1990.
  • PCR polymerase chain reaction
  • the kit may, optionally, further comprise a predetermined amount of a purified inventive JNK inhibitor sequence, an inventive chimeric peptide, or nucleic acids encoding these, for use as a diagnostic, standard, or control in the assays.
  • FIGS. 1A-C are diagrams showing alignments of conserved JBD domain regions in the indicated transcription factors. JNK inhibitor sequences were identified by inspecting these sequence alignments. The results of this alignment are exemplarily shown in FIGS. 1A-1 C.
  • FIG. I A depicts the region of highest homology between the JBDs of IB1, IB2, c-Jun and
  • Panel B depicts the amino acid sequence of the JBDs of L-IB1 (s) and L-IB1 for comparative reasons. Fully conserved residues are indicated by asterisks, while residues changed to Ala in the GFP-
  • FIG. 1 C shows the amino acid sequences of chimeric proteins that include a JNK inhibitor sequence and a trafficking sequence.
  • the trafficking sequence is derived from the human immunodeficiency virus (HIV) TAT polypeptide
  • the JNK inhibitor sequence is derived from an IBI (s) polypeptide.
  • Human, mouse, and rat sequences are identical in Panels B and C.
  • FIG. 2 is a diagram showing sequences of generic TAT-IB fusion peptides from human, mouse and rat.
  • FIG. 3 depicts the results from the evaluation of the neuroprotection against focal cerebral ischemia in a permanent MCAO model. Determination of the efficacy of the protection was carried out at different doses (see Figure 3). As can be seen from Figure 3, at least doses of 11 mg/kg, 3 nng/kg, 0.3 mg/kg and 0.03 mg/kg, contribute to a cerebral protection.
  • FIG. 4 illustrates the evaluation of neuroprotection by an inventive chimeric peptide according to SEQ ID NO: 11 after i.v. administration against focal cerebral ischemia, in a transient MCAO model. Subsequent to provoking ischemia in adult mice, the mice were killed 48 h after reperfusion. Serial cryostat sections were prepared and infarct volumes were calculated. As can be seen from Figure 4, the inventive chimeric peptide provides efficient neuroprotection.
  • FIG. 5 shows the results of an assay on neuronal cultures carried out by measuring LDH release following NMDA stimulation.
  • the results clearly indicate a neuroprotective effect of the inventive chimeric D- JNKH peptide (SEQ ID NO: 11 ), since degenerative changes due to NMDA exposure were completely inhibited as indicated by the absence of significant LDH release above controls.
  • FIG. 6 depicts the results of the inhibition of endogeneous JNK-activity in
  • FIG. 7 shows the protecting effect of D-TAT-IBI (s) Protection against permanent hearing loss. Changes of the hearing threshold level (dB sound pressure level) in guinea pigs following noise trauma (120 dB at 6 kHz during 30 minutes) at 8 kHz, the maximally impacted frequency, measured 20 minutes (temporary threshold shift, TTS, grey) and 15 days post noise exposure (permanent threshold shift).
  • D-TAT-IBI (black), which corresponds to permanent hearing loss, was determined after 15 days. As shown, D-TAT-IBI (s) not only protects substantially against permanent hearing loss from noise trauma if applied preventively before the noise exposure, but also in a time- dependent fashion if administered after trauma. PTS in treated ears was significantly lower for administration of D-TAT-IBI (s) 30 minutes and 4 hours post trauma than in untreated control ears.
  • Amino acid sequences important for efficient interaction with JNK were identified by sequence alignments between known JBDs.
  • a sequence comparison between the JBDs of IBl [SEQ ID NO: 13], IB2 [SEQ ID NO: 14], c-Jun [SEQ ID NO: 15] and ATF2 [SEQ ID NO: 16] defined a weakly conserved 8 amino acid sequence (FIG.1 A). Since the JBDs of IB1 and IB2 are approximately 100 fold as efficient as c- Jun or ATF2 in binding JNK (Dickens et al. Science 277: 693 (1997), it was reasoned that conserved residues between IB1 and IB2 must be important to confer maximal binding.
  • the comparison between the JBDs of IB1 and IB2 defined two blocks of seven and three amino acids that are highly conserved between the two sequences.
  • Inventive JNK inhibitor fusion proteins according to SEQ ID NO: 9 were synthesized by covalently linking the C-terminal end of SEQ ID NO: 1 to a N-terminal 10 amino acid long carrier peptide derived from the HIV-TAT4g 57 (Vives et al., J Biol. Chem. 272: 16010 (1997)) according to SEQ ID NO: 5 via a linker consisting of two proline residues. This linker was used to allow for maximal flexibility and prevent unwanted secondary structural changes.
  • the basic constructs were also prepared and designated L-IBl (s) (SEQ ID NO: 1) and L-TAT [SEQ ID NO: 5], respectively.
  • AII-D retro-inverso peptides according to SEQ ID NO: 11 were synthesized accordingly.
  • the basic constructs were also prepared and designated D-IB1 (s) [SEQ ID NO: 2] and D-TAT [SEQ ID NO: 6], respectively.
  • Oligonucleotides corresponding to JBD19 and comprising a conserved sequence of 19 amino acids as well as a sequence mutated at the fully conserved regions were synthesized and directionally inserted into the EcoRI and Sail sites of the pEGFP-N1 vector encoding the Green Fluorescent Protein (GFP) (from Clontech).
  • GFP Green Fluorescent Protein
  • Insulin producing ⁇ TC-3 cells were cultured in RPMI 1640 medium supplemented with 10% Fetal Calf Serum, 100 ⁇ g/mL Streptomycin, 100 units/mL Penicillin and 2 mM Glutamine. Insulin producing ⁇ TC-3 cells were transfected with the indicated vectors and IL-I ⁇ (10 ng/mL) was added to the cell culture medium.
  • the number of apoptotic cells was counted at 48 hours after the addition of I L-I ⁇ using an inverted fluorescence microscope. Apoptotic cells were discriminated from normal cells by the characteristic "blebbing out" of the cytoplasm and were counted after two days.
  • GFP Green Fluorescent protein expression vector used as a control
  • JBD19 is the vector expressing a chimeric GFP linked to the 19 aa sequence derived from the JBD of IBl
  • JBD19Mut is the same vector as GFP-JBD19, but with a JBD mutated at four conserved residues shown as FlG. 1 B
  • JBD L280 ' S the GFP vector linked to the entire JBD (aa 1 -280).
  • the GFP-JBD19 expressing construct prevented IL-I ⁇ induced pancreatic ⁇ -cell apoptosis as efficiently as the entire JBD L280 .
  • TAT-IB peptides L-TAT, D-TAT, inventive L-TAT-IBl (s), and inventive D-TAT-IBI (s) peptides [SEQ ID NOs: 5, 6, 9 and 12, respectively] were labeled by N-terminal addition of a glycine residue conjugated to fluorescein. Labeled peptides (1 ⁇ M) were added to ⁇ TC-3 cell cultures, which were maintained as described in Example 3.
  • Fluorescent signals from these all-D retro-inverso peptides were still very strong 1 week later, and the signal was only slightly diminished at 2 weeks post treatment.
  • Example 5 In vitro Inhibition of c-IUN, ATF2 and EIkI Phosphorylation
  • JNKs-mediated phosphorylation of their target transcription factors were investigated in vitro.
  • Recombinant and non activated JNK1 , JNK2 and JNK3 were produced using a TRANSCRIPTION AND TRANSLATION rabbit reticulocyte lysate kit (Promega) and used in solid phase kinase assays with c-Jun, ATF2 and EIkI , either alone or fused to glutathione-S- transferase (GST), as substrates.
  • GST glutathione-S- transferase
  • the kinase reactions were then initiated by the addition of 10 mM MgCI 2 and 5 pCi 33 P- ⁇ -dATP and 1 ⁇ g of either GST-Jun (aa 1-89), GST-AFT2 (aa 1-96) or GST-ELKl (aa 307-428).
  • GST-fusion proteins were purchased from Stratagene (La JoIIa, CA).
  • D-TAT, inventive D-TAT-IBI (s) and inventive L-TAT-IBI (s) peptides (0-250 ⁇ M dosage study) to inhibit GST-Jun (aa 1 -73) phosphorylation by recombinant JNKl, JNK2, and JNK3 by were analyzed as described above.
  • D-TAT-IBI (s) peptide decreased JNK-mediated phosphorylation of c-Jun, but at levels approximately 10- 20 fold less efficiently than L-TAT-IBKs).
  • L-TAT or inventive L-TAT-IBI (s) peptides on JNKs activated by stressful stimuli were evaluated using GST-Jun to pull down JNKs from UV-Iight irradiated HeLa cells or IL-I ⁇ treated PTC cells.
  • PTC cells were cultured as described above.
  • HeLa cells were cultured in DMEM medium supplemented with 10 % Fetal Calf Serum, 100 ⁇ g/mL Streptomycin, 100 units/ml Penicillin and 2 mM Glutamine.
  • PTC cells were activated with IL-I ⁇ as described above, whereas HeLa cells were activated by UV- Iight (20 J/m 2 ).
  • Cell extracts were prepared from control, UV-Iight irradiated HeLa cells and IL-I ⁇ treated ⁇ TC-3 cells by scraping the cell cultures in lysis buffer (20 mM Tris-acetate, 1 mM EGTA, 1 % Triton X-100, 10 mM p-nitrophenyl-phosphate, 5 mM sodium pyrophosphate, 10 mMP-glycerophosphate, 1 mM dithiothreitol). Debris was removed by centrifugation for five minutes at 15,000 rpm in an SS-34 Beckman rotor.
  • Example 7 In vivo inhibition of c-IUN phosphorylation by inventive TAT-lB(s) peptides
  • HeLa cells cultured as described above, were co-transfected with the 5xGAL-LUC reporter vector together with the GAL-Jun expression construct (Stratagene) comprising the activation domain of c-Jun (amino acids 1 -89) linked to the GAL4 DNA-binding domain.
  • GAL-Jun expression construct (Stratagene) comprising the activation domain of c-Jun (amino acids 1 -89) linked to the GAL4 DNA-binding domain.
  • Activation of JNK was achieved by the co-transfection of vectors expressing the directly upstream kinases MKK4 and MKK7 (see Whitmarsh et al., Science 285: 1573 (1999)).
  • 3x10 5 cells were transfected with the plasmids in 3.5-cm dishes using DOTAP (Boehringer Mannheim) following instructions from the manufacturer.
  • DOTAP Boehringer Mannheim
  • 20 ng of the plasmid was transfected withi ⁇ g of the reporter plasmid pFR-Luc (Stratagene) and 0.5 ⁇ g of either MKK4 or MKK7 expressing plasmids.
  • Three hours following transfection cell media were changed and TAT and TAT-IBl (s) peptides (1 ⁇ M) were added.
  • TAT-IBl (s) peptide blocked activation of c-Jun following MKK4 and MKK7 mediated activation of JNK. Because HeLa cells express JNK1 and JNK2 isoforms but not JNK3, we transfected cells with JNK3. Again, the TAT-IB(s) peptide inhibited JNK2 mediated activation of c-Jun.
  • Example 8 Inhibition Of IL-I ⁇ Induced Pancreatic ⁇ -Cell Death By TAT-IB Peptides
  • inventive L-TAT-IB(s) peptides were incubated for 30 minutes with 1 ⁇ M of inventive L-TAT-IBI (s) peptides followed by 10 ng/mL of IL-I . A second addition of peptide (1 ⁇ M) was performed 24 hours later. Apoptotic cells were counted after two days of incubation with IL-I ⁇ using propidium iodide (red stained cell are dead cells) and Hoechst 33342 (blue stained cell are cells with intact plasma membrane) nuclear staining. Addition of the inventive TAT-IB(s) peptides inhibited IL-I -induced apoptosis of ⁇ TC-3 cells cultured in the presence of
  • Peptides of the invention may be all-D amino acid peptides synthesized in reverse to prevent natural proteolysis (i.e. all-D retro-inverso peptides).
  • An all-D retro- inverso peptide of the invention would provide a peptide with functional properties similar to the native peptide, wherein the side groups of the component amino acids would correspond to the native peptide alignment, but would retain a protease resistant backbone.
  • Retro-inverso peptides of the invention are analogs synthesized using D-amino acids by attaching the amino acids in a peptide chain such that the sequence of amino acids in the retro-inverso peptide analog is exactly opposite of that in the selected peptide which serves as the model.
  • the retro-inverso peptide analog of this peptide would have the sequence RRRQRRKKRG [SEQ ID NO: 6].
  • the procedures for synthesizing a chain of D-amino acids to form the retro-inverso peptides are known in the art (see e.g. Jameson et al., Nature, 368,744-746 (1994); Brady et al., Nature, 368,692- 693 (1994); Guichard et al., J. Med. Chem. 39,2030-2039 (1996)).
  • the retro-peptides were produced by classical F-mock synthesis and further analyzed by Mass Spectrometry. They were finally purified by HPLC.
  • heterobivalent or heteromultivalent compounds of this invention will be prepared to include the "retro-inverso isomer" of the desired peptide.
  • Protecting the peptide from natural proteolysis should therefore increase the effectiveness of the specific heterobivaient or heteromultivalent compound, both by prolonging half-life and decreasing the extent of the immune response aimed at actively destroying the peptides.
  • SEM Standard Error of the Means
  • JNK is also activated by ionizing radiation.
  • inventive TAT- IB(s) peptides would provide protection against radiation-induced JNK damage.
  • "WiDr” cells were irradiated (30 Gy) in presence or absence of D-TAT, inventive L- TAT-IB1 (s) or inventive D-TAT-IBI (s) peptides (1 ⁇ M added 30 minutes before irradiation).
  • Control cells CRL
  • Inventive L-TAT-IBI (s) and D-TAT-IBI (s) peptides were both able to prevent irradiation induced apoptosis in this human colon cancer line.
  • mice C57B1/6 mice (2 to 3 months old) were irradiated with a Phillips RT 250 R-ray at a dose rate of 0.74 Gy/min (17 mA, 0.5 mm Cu filter). Thirty minutes prior to irradiation, the animals were injected i.p. with either TAT, inventive L-TAT-IBI (s) or inventive D-TAT-IBI (s) peptides (301 of a 1 mM solution). Briefly, mice were irradiated as follows: mice were placed in small plastic boxes with the head lying outside the box. The animals were placed on their back under the irradiator, and their neck fixed in a small plastic tunnel to maintain their head in a correct position. The body was protected with lead.
  • mice Prior to irradiation mice were maintained on standard pellet mouse chow, however post irradiation mice were fed with a semi-liquid food that was renewed each day.
  • the reaction of the lip mucosa was then scored by 2 independent observers according to the scoring system developed by Parkins et al. (Parkins et al, Radiotherapy & Oncology, 1 : 165-173, 1983), in which the erythema status as well as the presence of edema, desquamation and exudation was quoted. Additionally, animals were weighed before each recording of their erythema/edema status.
  • Inventive L-TAT-IBI (s) peptides decrease the formation of the AP-1 DNA binding complex in the presence of TNF- ⁇ .
  • Example 14 Evaluation of the neuroprotection against focal cerebral ischemia, in a permanent MCAO model - Determination of the efficacity of the protection at different doses, (see Figure 3)
  • Focal cerebral ischemia was induced in 12-days-old rats. Pups were anesthetized in an induction chamber with 2% isoflurane and during the operation anaesthesia was maintained using a mask under 2% isoflurane.
  • MCAO was induced by electrocoagulating a main branch of the middle cerebral artery (MCA). Rats were placed on the right side, and an oblique dermal incision was made between the ear and eye. After excision of the temporal muscle, the cranial bone was removed from the frontal suture to a level below the zygomatic arch.
  • the left MCA exposed just after its apparition over the rhinal fissure, was permanently electrocoagulated at the inferior cerebral vein level before the MCA bifurcated into frontal and parietal branches. The cranial skin incision was then closed. Rat pups were then placed in an incubator maintained at 37°C until they awoke, and were then transferred to their mother. 6 hours later an inventive chimeric D-TAT-IBl (s) peptide according to SEQ ID NO: 11 was injected intraperitoneal ⁇ . 24 hours after the coagulation, the rats were anesthetized with chloral hydrate and perfused through the ascending aorta with 4% paraformaldehyde in PBS.
  • Brains were then removed and kept for 2 hours in the same fixative solution, and placed in a gradient of 30% sucrose in PBS for about 15 hours at 4°C. Brains were frozen in isopentane (-4O 0 C) and stored at -20 0 C. Coronal cryostat sections of 50 ⁇ m were collected on glass slides. The sections were stained with cresyl violet. Each tenth section was analyzed and the total volume of the lesion was calculated using the Neuroleucida programme. In the control group A,
  • Example 15 Evaluation of neuroprotection by inventive chimeric peptides after iv administration against focal cerebral ischaemia, in a transient MCAO model (see Figure 4).
  • mice Transient ischemia in adult mice.
  • ICR-CD1 mice (6 weeks old; 18-37 g; Harlan)
  • we provoked ischemia by introducing a filament from the common carotid artery into the internal carotid and advancing it into the arterial circle, thereby occluding the middle cerebral artery.
  • mice model The infarct volume sizes (mm ) after bolus iv administration of placebo and XG-102 0.3, 1,3 mg/kg 6 hours after reperfusion (30 minutes clamp) in an adult mice model were as follows.
  • Example 16 Assay on neuronal cultures by measuring LPH release following NMDA stimulation (see Figure 5).
  • the neuroprotective effect of the D-TAT-IB (generic)(s)/D-JNKI1 peptide was evaluated in sister cultures pre-treated for 30 min with the indicated concentrations of peptides or MK-801 before continuous exposure to 100 ⁇ M NMDA. After 12 h of NMDA treatment, in cultures pretreated with 5 ⁇ M of D-TAT- IB (generic)(s)/D-JNKI1 the degenerative changes due to NMDA exposure were completely inhibited as indicated by the absence of significant LDH release above controls (Fig. 5). The morphological appearance, number and distribution of the neurons were indistinguishable from the controls. Cortical neuronal culture.
  • the plating medium consisted of B27/Neurobasal (Life Technologies, Gaithersburg, MD) supplemented with 0.5mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin.
  • Lactate dehydrogenate (LDH) cytotoxicity assay Lactate dehydrogenate (LDH) cytotoxicity assay. LDH released into the bathing medium 12, 24 and 48 h after NMDA administration was measured using the Cytotox 96 non-radioactive cytotoxicity assay kit (Promega, Wl) (see Fig. 5).
  • Example 17 Inhibition of endogenous INK activity in HepG2 cells using an all-in one well approach (see Figure 6).
  • AlphaScreen is a non-radioactive bead-based technology used to study biomolecular interactions in a microplate format.
  • ALPHA Amplified Luminescence Proximity Homogenous Assay. It involves a biological interaction that brings a "donor” and an “acceptor” beads in close proximity, then a cascade of chemical reactions acts to produce an amplified signal. Upon laser excitation at 680 nm, a photosensitizer (phthalocyanine) in the "donor" bead converts ambient oxygen to an excited singlet state.
  • the singlet oxygen molecule can diffuse up to approximately 200 nm in solution and if an acceptor bead is within that proximity, the singlet oxygen reacts with a thioxene derivative in the "acceptor" bead, generating chemiluminescence at 370 nm that further activates fluorophores contained in the same "acceptor” bead. The excited fluorophores subsequently emit light at 520-620 nm. In the absence of an acceptor bead, singlet oxygen falls to ground state and no signal is produced.
  • kinase reagents (B-GST-cjun, anti P-cJun antibody and active JNK3) were first diluted in kinase buffer (20 mM Tris-HCI pH 7.6, 10 mM MgCI 2 , 1 mM DTT, 100 ⁇ M Na 3 VO 4 , 0.01% Tween-20) and added to wells (15 ⁇ l). Reactions were then incubated in presence of 10 ⁇ M of ATP for 1 h at 23°C.
  • Detection was performed by an addition of 10 ⁇ l of beads mix (Protein A acceptor 20 ⁇ g/ml and Streptavidin donor 20 ⁇ g/ml), diluted in detection buffer (20 mM Tris-HCI pH 7.4, 20 mM NaCI, 80 mM EDTA, 0.3% BSA), followed by an another one-hour incubation at 23°C in the dark.
  • detection buffer 20 mM Tris-HCI pH 7.4, 20 mM NaCI, 80 mM EDTA, 0.3% BSA
  • kinase assays were performed as described above except active JNK3 was replaced by cells lysates and reaction kinase components were added after the cells lysis.
  • B-GST-cjun and P-cJun antibody were used at the same concentrations whereas ATP was used at 50 ⁇ M instead of 10 ⁇ M.
  • AIphaScreen signal was analyzed directly on the Fusion or En Vision apparatus.
  • D-TAT-IBI was applied onto the round window membrane of the cochlea of 3 groups of guinea pigs (each group with 6 animals) in 2 microliters of a gel formulation of 2.6% buffered hyaluronic acid (Hylumed, Genzyme Corp.) at a concentration of 100 ⁇ M either 30 minutes before noise trauma (120 dB at 6 kHz during 30 minutes) or 30 minutes or 4 hours thereafter. Untreated ears served as control. Hearing threshold shifts were evaluated by auditory brainstem response measurements 20 minutes after noise trauma (temporary threshold shift, TTS) and 15 days following the trauma (permanent threshold shift, PTS).
  • TTS temporary threshold shift
  • PTS permanent threshold shift
  • D- TAT-IB1 (s) protected against permanent hearing loss even if applied after exposure to excessive noise compared to non-treated ears.
  • the protective effect was stronger the earlier D- TAT-IBl (s) was administered after the noise trauma.
  • D- TAT- IBl (s) is a very effective otoprotective compound in case of noise trauma.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
PCT/EP2005/009782 2005-09-12 2005-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway WO2007031098A1 (en)

Priority Applications (45)

Application Number Priority Date Filing Date Title
PCT/EP2005/009782 WO2007031098A1 (en) 2005-09-12 2005-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
PCT/EP2006/008882 WO2007031280A2 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
MEP-2014-123A ME02000B (me) 2005-09-12 2006-09-12 Peptidni inhibitori jnk signalnog transdukcijskog puta koji su permeabilni za ćeliju
SI200631345T SI1928903T1 (sl) 2005-09-12 2006-09-12 Celično permeabilni peptidni inhibitorji poti transdukcije JNK signala
ZA200800848A ZA200800848B (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
JP2008530405A JP5386169B2 (ja) 2005-09-12 2006-09-12 Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤
PL11003985T PL2418217T4 (pl) 2005-09-12 2006-09-12 Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK
HUE11003985A HUE029132T2 (en) 2005-09-12 2006-09-12 JNK signal transduction synthesis pathway is a cell-permeable peptide inhibitor
MEP-2016-62A ME02426B (me) 2005-09-12 2006-09-12 Peptidni inhibitori jnk signalnog transdukcijskog puta koji su permeabilni za ćeliju
ES11003985.6T ES2567708T3 (es) 2005-09-12 2006-09-12 Inhibidores peptídicos de la vía de transducción de la señal de JNK con permeabilidad celular
DK11003985.6T DK2418217T3 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the JNK signal transduction pathway.
CN2006800333412A CN101263157B (zh) 2005-09-12 2006-09-12 Jnk信号转导通路的细胞通透肽抑制剂
EP15002528.6A EP3012266A1 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
BRPI0616824A BRPI0616824B8 (pt) 2005-09-12 2006-09-12 peptídeo quimérico, seu uso, composição farmacêutica compreendendo o mesmo, e kit
ES06792004T ES2388076T3 (es) 2005-09-12 2006-09-12 Inhibidores peptídicos de permeabilidad celular de la vía de transducción de la señal de JNK
KR1020087006094A KR101305533B1 (ko) 2005-09-12 2006-09-12 Ｊｎｋ 신호 전달 경로의 세포 투과성 펩티드 억제제
DK06792004.1T DK1928903T3 (da) 2005-09-12 2006-09-12 Celle-permeable peptidinhibitorer af JNK-signaltransduktionsvejen
EP11003985.6A EP2418217B1 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
PL06792004T PL1928903T3 (pl) 2005-09-12 2006-09-12 Przenikające przez komórki inhibitory białkowe szlaku przekazywania sygnałów przez JNK
EA200800680A EA014330B1 (ru) 2005-09-12 2006-09-12 Пептидные ингибиторы пути трансдукции сигнала jnk, обладающие способностью проникать в клетку
CA2621337A CA2621337C (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
EP06792004A EP1928903B1 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
PT06792004T PT1928903E (pt) 2005-09-12 2006-09-12 Inibidores peptídicos de permeação celular da via de transdução de sinal de jnk
US12/066,657 US8748395B2 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
RS20120310A RS52379B (en) 2005-09-12 2006-09-12 PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUTION ROUTE PERMEABLE TO THE CELL
UAA200804223A UA98101C2 (ru) 2005-09-12 2006-09-12 Пептидные ингибиторы пути трансдукции сигнала jnk, которые имеют способность проникать в клетку
SI200632044A SI2418217T1 (sl) 2005-09-12 2006-09-12 Celično permeabilni peptidni inhibitorji poti transdukcije JNK signala
AU2006291541A AU2006291541B2 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
RS20160222A RS54701B1 (en) 2005-09-12 2006-09-12 PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUTION ROUTE PERMEABLE TO THE CELL
IL189133A IL189133A (en) 2005-09-12 2008-01-30 Cell-permeable peptide inhibitors of the jnk signal transfer pathway
NO20081664A NO342272B1 (no) 2005-09-12 2008-04-04 JNK-inhibitorsekvens, kimært peptid, farmasøytisk sammensetning og anvendelse av disse.
HK08112945.3A HK1118841A1 (en) 2005-09-12 2008-11-26 Cell-permeable peptide inhibitors of the jnk signal transduction pathway jnk
JP2012000381A JP5727393B2 (ja) 2005-09-12 2012-01-05 Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤
HK12104474.3A HK1163712A1 (zh) 2005-09-12 2012-05-08 信號轉導途徑的細胞可通透肽抑制劑
CY20121100593T CY1112924T1 (el) 2005-09-12 2012-07-04 Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
HRP20120598TT HRP20120598T1 (hr) 2005-09-12 2012-07-19 Stanično permeabilni peptidni inhibitori jnk signalnog transdukcijskog puta
US14/144,938 US9290538B2 (en) 2005-09-12 2013-12-31 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
JP2014216270A JP2015034171A (ja) 2005-09-12 2014-10-23 Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤
IL237984A IL237984A0 (en) 2005-09-12 2015-03-26 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US15/045,058 US20160264630A1 (en) 2005-09-12 2016-02-16 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
CY20161100290T CY1117351T1 (el) 2005-09-12 2016-04-11 Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης
HRP20160379TT HRP20160379T1 (hr) 2005-09-12 2016-04-12 Stanično permeabilni peptidni inhibitori jnk signalnog transdukcijskog puta
HK16112196.9A HK1223948A1 (zh) 2005-09-12 2016-10-24 信號轉導途徑的細胞可通透肽抑制劑
US15/628,771 US20170320917A1 (en) 2005-09-12 2017-06-21 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
US16/525,234 US20200062805A1 (en) 2005-09-12 2019-07-29 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/009782 WO2007031098A1 (en) 2005-09-12 2005-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Publications (1)

Publication Number Publication Date
WO2007031098A1 true WO2007031098A1 (en) 2007-03-22

Family

ID=35686501

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2005/009782 WO2007031098A1 (en) 2005-09-12 2005-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
PCT/EP2006/008882 WO2007031280A2 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/008882 WO2007031280A2 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Country Status (25)

Country Link
US (5) US8748395B2 (pl)
EP (3) EP1928903B1 (pl)
JP (3) JP5386169B2 (pl)
KR (1) KR101305533B1 (pl)
CN (1) CN101263157B (pl)
AU (1) AU2006291541B2 (pl)
BR (1) BRPI0616824B8 (pl)
CA (1) CA2621337C (pl)
CY (2) CY1112924T1 (pl)
DK (2) DK1928903T3 (pl)
EA (1) EA014330B1 (pl)
ES (2) ES2567708T3 (pl)
HK (3) HK1118841A1 (pl)
HR (2) HRP20120598T1 (pl)
HU (1) HUE029132T2 (pl)
IL (2) IL189133A (pl)
ME (2) ME02000B (pl)
NO (1) NO342272B1 (pl)
PL (2) PL2418217T4 (pl)
PT (1) PT1928903E (pl)
RS (2) RS54701B1 (pl)
SI (2) SI2418217T1 (pl)
UA (1) UA98101C2 (pl)
WO (2) WO2007031098A1 (pl)
ZA (1) ZA200800848B (pl)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154700A1 (en) * 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009144038A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
GB2461961A (en) * 2008-07-14 2010-01-27 Otonomy Inc Sterile anti-apoptotic agent for treatment of ear diseases
WO2010151638A1 (en) * 2009-06-25 2010-12-29 Medical College Of Georgia Research Institute, Inc. Jnk inhibitors for use in treating spinal muscular atrophy
US8030297B2 (en) 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
US8063012B2 (en) 2006-09-19 2011-11-22 Phylogica Limited Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2011160653A1 (en) * 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8236924B2 (en) 1999-10-12 2012-08-07 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
WO2013079213A1 (en) * 2011-11-30 2013-06-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8748395B2 (en) 2005-09-12 2014-06-10 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8852626B2 (en) 2008-06-27 2014-10-07 Otonomy, Inc. Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
WO2014206563A3 (en) * 2013-06-26 2015-03-19 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US9132087B2 (en) 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9173864B2 (en) 2008-10-22 2015-11-03 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders
US10023615B2 (en) 2008-12-22 2018-07-17 Xigen Inflammation Ltd. Efficient transport into white blood cells
US10092580B2 (en) 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US10596223B2 (en) 2011-12-21 2020-03-24 Xigen Inflammation Ltd. JNK inhibitor molecules for treatment of various diseases
CN111655228A (zh) * 2017-05-03 2020-09-11 J·左 预防和治疗听力损失的组合物和方法
US11040004B2 (en) 2016-09-16 2021-06-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
US11331364B2 (en) 2014-06-26 2022-05-17 Xigen Inflammation Ltd. Use for JNK inhibitor molecules for treatment of various diseases
US11779628B2 (en) 2013-06-26 2023-10-10 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102365093A (zh) 2009-03-30 2012-02-29 参天制药株式会社 用于视网膜疾病的预防剂或治疗剂和使用JNK(c-Jun氨基末端激酶)抑制肽预防或治疗视网膜疾病的方法以及所述肽的用途
WO2015197193A2 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2016055160A2 (en) 2014-10-08 2016-04-14 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197098A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206426A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US9926354B2 (en) 2014-01-09 2018-03-27 University Of South Florida Amyloid precursor protein (APP) based Ã#-secretase inhibitor peptides, and methods of use
CN106455579A (zh) * 2014-04-23 2017-02-22 耳瑞思医学股份有限公司 用于治疗和预防耳鸣的方法和组合物
WO2015200768A2 (en) * 2014-06-26 2015-12-30 Auris Medical Ag Pharmacologic treatments of menière's disease
EP3234110B1 (en) 2014-12-18 2024-02-28 President and Fellows of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
US10654894B2 (en) 2016-02-03 2020-05-19 Keenesaw State University Research And Service Foundation, Inc. Methods for delivering cargo into a cell by using signal molecules as cell penetration agents
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
IT202000011176A1 (it) 2020-05-15 2021-11-15 Univ Degli Studi Milano Peptidi inibitori di jnk3
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027268A2 (en) * 1999-10-12 2001-04-19 University Of Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195304B (it) 1981-12-22 1988-10-12 Anic Spa Metodo per la preparazione di gem-diammino derivati n-monoacilati
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IT1190389B (it) 1985-09-19 1988-02-16 Eniricerche Spa Esapeptidi ad attivita' ipotensiva
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IT1227907B (it) 1988-12-23 1991-05-14 Eniricerche S P A Milano Sclav Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1992018138A1 (en) 1991-04-10 1992-10-29 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
US5350835A (en) 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
US5994108A (en) 1991-11-05 1999-11-30 Board Of Regents, The University Of Texas System Mutant TAR virus and transdominant tat mutants as pharmacological agents
JPH07505283A (ja) 1992-03-20 1995-06-15 ベイラー・カレッジ・オブ・メディシン Ｄｎａトランスポーター系および使用方法
CA2133323C (en) 1992-04-03 2010-10-26 Francis C. Szoka, Jr. Self-assembling polynucleotide delivery system
WO1994004562A1 (en) 1992-08-13 1994-03-03 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
JP2702285B2 (ja) 1992-08-21 1998-01-21 バイオジェン，インコーポレイテッド Ｔａｔ由来の輸送ポリペプチド
CN1091138A (zh) 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
US5545551A (en) 1992-08-28 1996-08-13 Mt. Sinai School Of Medicine Of The City University Of New York Cloning and expression of pur protein
ATE200625T1 (de) 1992-10-09 2001-05-15 Advanced Tissue Sciences Inc Leberreservezellen
EP0693939A1 (de) 1993-04-14 1996-01-31 Roche Diagnostics GmbH Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
CA2153480A1 (en) 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
JPH10508205A (ja) 1995-04-25 1998-08-18 バクスター インターナショナル インコーポレイテッド 肝細胞および膵臓ランゲルハンス島細胞を単離するためのコラーゲナーゼおよびキモパパインを含有する組成物
ATE365808T1 (de) 1995-07-28 2007-07-15 Marie Curie Cancer Care Transportproteine und deren verwendungen
WO1997010836A1 (en) 1995-09-21 1997-03-27 Innapharma, Inc. Peptides and peptidomimetics inhibiting the oncogenic action of p21 ras
IE80466B1 (en) 1995-11-10 1998-07-29 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US6630351B1 (en) 1999-06-07 2003-10-07 Mirus Corporation Compositions and methods for drug delivery using pH sensitive molecules
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US6187817B1 (en) 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO1998023781A1 (en) 1996-11-26 1998-06-04 Johns Hopkins University Ligand detection system and methods of use thereof
US5989814A (en) 1997-04-01 1999-11-23 Reagents Of The University Of California Screening methods in eucaryotic cells
US5880261A (en) 1997-04-03 1999-03-09 Waeber; Gerard Transcription factor Islet-Brain 1 (IB1)
WO1998047913A2 (en) 1997-04-18 1998-10-29 The University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
EP1019071A4 (en) 1997-05-15 2003-07-30 Cytogen Corp Arbitrary peptides which transport receptors of the gastro-intestinal tract bind and process with it
US20040152084A1 (en) 2003-01-31 2004-08-05 Slattum Paul M. Compounds and processes for single-pot attachment of a label to nucleic acid
AU734827B2 (en) 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
FR2767323B1 (fr) 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
EP0897002A3 (en) 1997-08-14 2001-10-04 Smithkline Beecham Plc U62317, a protein having a JNK-binding domain
AU9402898A (en) 1997-09-26 1999-04-23 Washington University Cell death agonists
US6420031B1 (en) 1997-11-03 2002-07-16 The Trustees Of Princeton University Highly transparent non-metallic cathodes
CA2306870A1 (en) 1997-10-20 1999-04-29 David Michael Goldstein Bicyclic kinase inhibitors
US6270956B1 (en) 1997-12-11 2001-08-07 The Salk Institute For Biological Studies Transcriptional coactivator that interacts with Tat protein and regulates its binding to TAR RNA, methods for modulating Tat transactivation, and uses therefor
EP0947524A1 (en) 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
CA2330458A1 (en) 1998-04-29 1999-11-04 Georgetown University Methods of identifying and using hla binding compounds as hla-agonists and antagonists
CA2327354A1 (en) 1998-05-13 1999-11-18 Incyte Pharmaceuticals, Inc. Human apoptosis associated proteins
AU3714499A (en) 1998-05-14 1999-11-29 Pasteur Merieux Serums Et Vaccins Hepatitis c virus mimotopes
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
CA2331384A1 (en) 1998-06-18 1999-12-23 Dnavec Research Inc. Nucleic acid transfer phage
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6348185B1 (en) 1998-06-20 2002-02-19 Washington University School Of Medicine Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
JP2002528562A (ja) 1998-08-28 2002-09-03 グリフォン サイエンシーズ 長さのばらつきが小さいポリアミド連鎖、その連鎖の製造方法およびその連鎖とタンパク質の複合体
ATE361752T1 (de) 1998-09-25 2007-06-15 Cephalon Inc Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen
US6656474B1 (en) 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
AU765983B2 (en) 1999-05-28 2003-10-09 Apoptosis Technology, Inc. Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
WO2000075118A1 (en) 1999-06-03 2000-12-14 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)
EP1210121A2 (en) 1999-08-24 2002-06-05 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6881825B1 (en) 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
AU778929B2 (en) 1999-12-06 2004-12-23 General Hospital Corporation, The Pancreatic stem cells and their use in transplantation
US6586403B1 (en) 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AU2002220979A1 (en) 2000-10-13 2002-04-22 Xigen Sa Intracellular delivery of biological effectors by novel transporter peptide sequences
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
AU2002211122B2 (en) 2000-10-17 2005-06-23 Diatranz Otsuka Limited Preparation and xenotransplantation or porcine islets
US20030077826A1 (en) 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
WO2002062396A2 (en) 2001-02-08 2002-08-15 University Of Medicine And Dentistry Of New Jersey Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
ATE437647T1 (de) 2001-02-16 2009-08-15 Cellgate Inc Transporter mit beabstandeten arginin-teilchen
JP4234999B2 (ja) 2001-04-06 2009-03-04 トマス ジェファソン ユニバーシティ 治療標的としてのｈｉｖ−１ｖｉｆタンパク質の多量体形成
DE10117281A1 (de) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
AU2002322519A1 (en) 2001-07-17 2003-03-03 Incyte Genomics, Inc. Proteins associated with cell growth, differentiation, and death
CA2466243A1 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
US7803749B2 (en) 2002-01-09 2010-09-28 Xigen Sa Peptide inhibitors of MKK7 kinase binding to insulin binding proteins
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
AU2003267124A1 (en) 2002-09-09 2004-03-29 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
WO2004026406A1 (en) 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
DE50209178D1 (de) 2002-10-11 2007-02-15 Imvision Gmbh Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen
US20040186052A1 (en) 2002-10-24 2004-09-23 Suhasini Iyer Cytomodulating peptides and methods for treating neurological disorders
EP1578365A4 (en) 2002-11-14 2009-09-23 Arbor Vita Corp MOLECULAR INTERACTIONS IN NEURONS
WO2004054501A2 (en) 2002-11-18 2004-07-01 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20050019366A1 (en) 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
EP1599475A2 (en) 2003-03-06 2005-11-30 Eisai Co., Ltd. Jnk inhibitors
WO2004092339A2 (en) 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
ES2500921T3 (es) 2003-04-29 2014-10-01 Sarepta Therapeutics, Inc. Composiciones para potenciar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células
EP1732581A4 (en) 2003-06-20 2008-06-04 Univ California San Diego POLYPEPTIDE TRANSDUCTION AND FUSOGENIC PEPTIDES
KR100685345B1 (ko) 2004-03-27 2007-02-22 학교법인조선대학교 세포사 유도 펩타이드
UA91676C2 (ru) 2004-04-08 2010-08-25 Эплайд Рисерч Системз Эрс Холдинг Н.В. Композиция, которая содержит ингибитор jnk и циклоспорин
WO2006021458A2 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
EP1656951A1 (en) 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
US20070015779A1 (en) 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20060258706A1 (en) 2005-04-29 2006-11-16 Manohar Saindane Solid forms of a JNK inhibitor
US20070003531A1 (en) 2005-06-30 2007-01-04 University Of Connecticut Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US10045953B2 (en) 2006-07-06 2018-08-14 Case Western Reserve University Ceramide composition and method of use
WO2008094208A2 (en) 2006-08-02 2008-08-07 Northwestern University Protein kinase targeted therapeutics
MX2009002229A (es) 2006-09-08 2009-03-16 Hoffmann La Roche Benzotriazoles como moduladores de cinasas.
EP2074138A4 (en) * 2006-09-19 2009-12-30 Phylogica Ltd NEUROPROTECTIVE PEPTIDE AP-1 SIGNALING INHIBITORS AND USES THEREOF
GB0702259D0 (en) 2007-02-06 2007-03-14 Eisai London Res Lab Ltd 7-azaindole derivatives
SI2915529T1 (sl) 2008-05-07 2017-09-29 The Regents Of The University Of California Terapevtska regeneracija in obogatitev lubrikacije okularne površine
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
US20100183633A1 (en) 2008-12-04 2010-07-22 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
CN102365093A (zh) 2009-03-30 2012-02-29 参天制药株式会社 用于视网膜疾病的预防剂或治疗剂和使用JNK(c-Jun氨基末端激酶)抑制肽预防或治疗视网膜疾病的方法以及所述肽的用途
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
ES2575226T3 (es) 2010-10-14 2016-06-27 Xigen Inflammation Ltd. Péptidos permeables celulares inhibidores de la ruta de transducción de la señal JNK para su uso en el tratamiento de la uiveítis
US8471027B2 (en) 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206426A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027268A2 (en) * 1999-10-12 2001-04-19 University Of Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARR R K ET AL: "IDENTIFICATION OF THE CRITICAL FEATURES OF A SMALL PEPTIDE INHIBITOR OF JNK ACTIVITY", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC.,, US, vol. 277, no. 13, 29 March 2002 (2002-03-29), pages 10987 - 10997, XP001155759, ISSN: 0021-9258 *
BONNY C ET AL: "Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death", DIABETES, NEW YORK, NY, US, vol. 50, no. 1, January 2001 (2001-01-01), pages 77 - 82, XP002274267, ISSN: 0012-1797 *
BONNY CHRISTOPHE ET AL: "Targeting the JNK pathway as a therapeutic protective strategy for nervous system diseases.", REVIEWS IN THE NEUROSCIENCES. 2005, vol. 16, no. 1, 2005, pages 57 - 67, XP009061133, ISSN: 0334-1763 *
BORSELLO TIZIANA ET AL: "A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia.", NATURE MEDICINE. SEP 2003, vol. 9, no. 9, September 2003 (2003-09-01), pages 1180 - 1186, XP002366119, ISSN: 1078-8956 *
BORSELLO TIZIANA ET AL: "Use of cell-permeable peptides to prevent neuronal degeneration.", TRENDS IN MOLECULAR MEDICINE. MAY 2004, vol. 10, no. 5, May 2004 (2004-05-01), pages 239 - 244, XP002366120, ISSN: 1471-4914 *
DATABASE UniProt 28 February 2003 (2003-02-28), XP002366175, retrieved from EBI Database accession no. Q9WVI9 *
VIVES E ET AL: "A TRUNCATED HIV-1 TAT PROTEIN BASIC DOMAIN RAPIDLY TRANSLOCATES THROUGH THE PLASMA MEMBRANE AND ACCUMULATES IN THE CELL NUCLEUS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 272, no. 25, 1997, pages 16010 - 16017, XP002931299, ISSN: 0021-9258 *

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569447B2 (en) 1999-10-12 2013-10-29 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8278413B2 (en) 1999-10-12 2012-10-02 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8236924B2 (en) 1999-10-12 2012-08-07 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US9290538B2 (en) 2005-09-12 2016-03-22 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8748395B2 (en) 2005-09-12 2014-06-10 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8063012B2 (en) 2006-09-19 2011-11-22 Phylogica Limited Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor
US8946381B2 (en) 2006-09-19 2015-02-03 Phylogica Limited Compositions and uses thereof for the treatment of wounds
US8822409B2 (en) 2007-06-20 2014-09-02 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
WO2008154700A1 (en) * 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
US10272034B2 (en) 2008-04-21 2019-04-30 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US10751281B2 (en) 2008-04-21 2020-08-25 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11123285B2 (en) 2008-04-21 2021-09-21 Otonomy, Inc. Auris formulations for treating OTIC diseases and conditions
US11123286B2 (en) 2008-04-21 2021-09-21 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US9132087B2 (en) 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US9744126B2 (en) 2008-05-14 2017-08-29 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8546363B2 (en) 2008-05-14 2013-10-01 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8680083B2 (en) 2008-05-14 2014-03-25 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8680082B2 (en) 2008-05-14 2014-03-25 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8030297B2 (en) 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
US8658626B2 (en) 2008-05-14 2014-02-25 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8828980B2 (en) 2008-05-14 2014-09-09 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US9511020B2 (en) 2008-05-14 2016-12-06 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
EP2650008A1 (en) * 2008-05-30 2013-10-16 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various cardiovascular diseases
EP2491942A1 (en) * 2008-05-30 2012-08-29 Xigen S.A. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
US9006185B2 (en) 2008-05-30 2015-04-14 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
JP2011521919A (ja) * 2008-05-30 2011-07-28 ザイジェン エス．アー． Ｊｎｋシグナル伝達経路の細胞透過性のペプチド性阻害剤の、慢性または非慢性の炎症性消化器疾患の治療のための、使用
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2009253347B2 (en) * 2008-05-30 2014-01-30 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
US9180159B2 (en) 2008-05-30 2015-11-10 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
EP2985031A1 (en) * 2008-05-30 2016-02-17 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN102112149A (zh) * 2008-05-30 2011-06-29 希根有限责任公司 Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗各种疾病的应用
EP2650007A1 (en) * 2008-05-30 2013-10-16 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various cardiovascular diseases
WO2009144037A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2009253346B2 (en) * 2008-05-30 2014-07-10 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
EP2489362A1 (en) * 2008-05-30 2012-08-22 Xigen S.A. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
EP2489361A1 (en) * 2008-05-30 2012-08-22 Xigen S.A. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
US9610330B2 (en) 2008-05-30 2017-04-04 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
CN102112148A (zh) * 2008-05-30 2011-06-29 希根有限责任公司 Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗慢性或非慢性炎性消化病的应用
WO2009144038A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US10232044B2 (en) 2008-06-18 2019-03-19 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US10918594B2 (en) 2008-06-27 2021-02-16 Otonomy, Inc. Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
US9333171B2 (en) 2008-06-27 2016-05-10 Otonomy, Inc. Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
US8852626B2 (en) 2008-06-27 2014-10-07 Otonomy, Inc. Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
GB2461961A (en) * 2008-07-14 2010-01-27 Otonomy Inc Sterile anti-apoptotic agent for treatment of ear diseases
US9867778B2 (en) 2008-07-21 2018-01-16 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US9233068B2 (en) 2008-07-21 2016-01-12 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders
US10092580B2 (en) 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8575122B2 (en) 2008-07-21 2013-11-05 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US11369566B2 (en) 2008-07-21 2022-06-28 Alk-Abelló, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US9066855B2 (en) 2008-07-21 2015-06-30 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US9427472B2 (en) 2008-07-21 2016-08-30 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US9205048B2 (en) 2008-07-21 2015-12-08 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US9603796B2 (en) 2008-07-21 2017-03-28 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US10772828B2 (en) 2008-07-21 2020-09-15 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US9808460B2 (en) 2008-07-21 2017-11-07 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US9173864B2 (en) 2008-10-22 2015-11-03 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
US10023615B2 (en) 2008-12-22 2018-07-17 Xigen Inflammation Ltd. Efficient transport into white blood cells
WO2010151638A1 (en) * 2009-06-25 2010-12-29 Medical College Of Georgia Research Institute, Inc. Jnk inhibitors for use in treating spinal muscular atrophy
WO2011160827A3 (en) * 2010-06-21 2012-02-23 Xigen S.A. Novel jnk inhibitor molecules
US9624267B2 (en) 2010-06-21 2017-04-18 Xigen Inflammation Ltd. JNK inhibitor molecules
EP2993180A1 (en) * 2010-06-21 2016-03-09 Xigen Inflammation Ltd. Novel jnk inhibitor molecules
US8981052B2 (en) 2010-06-21 2015-03-17 Xigen Inflammation Ltd. JNK inhibitor molecules
WO2011160653A1 (en) * 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013079213A1 (en) * 2011-11-30 2013-06-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome
US10596223B2 (en) 2011-12-21 2020-03-24 Xigen Inflammation Ltd. JNK inhibitor molecules for treatment of various diseases
US10624948B2 (en) 2013-06-26 2020-04-21 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
US11779628B2 (en) 2013-06-26 2023-10-10 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2014206563A3 (en) * 2013-06-26 2015-03-19 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders
US11331364B2 (en) 2014-06-26 2022-05-17 Xigen Inflammation Ltd. Use for JNK inhibitor molecules for treatment of various diseases
US11040004B2 (en) 2016-09-16 2021-06-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
EP3618807A4 (en) * 2017-05-03 2021-01-20 Jian Zuo COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS
US11883491B2 (en) 2017-05-03 2024-01-30 St. Jude Children's Research Hospital, Inc. Compositions and methods for prevention and treatment of hearing loss
CN111655228B (zh) * 2017-05-03 2024-02-09 听治疗有限责任公司 预防和治疗听力损失的组合物和方法
CN111655228A (zh) * 2017-05-03 2020-09-11 J·左 预防和治疗听力损失的组合物和方法
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss

Also Published As

Publication number Publication date
CN101263157A (zh) 2008-09-10
BRPI0616824B8 (pt) 2021-05-25
ZA200800848B (en) 2009-05-27
CY1112924T1 (el) 2016-04-13
EP2418217B1 (en) 2016-01-27
DK2418217T3 (en) 2016-03-21
IL189133A (en) 2015-04-30
WO2007031280A3 (en) 2007-05-24
HK1223948A1 (zh) 2017-08-11
JP2015034171A (ja) 2015-02-19
CN101263157B (zh) 2012-11-07
HK1118841A1 (en) 2009-02-20
BRPI0616824A2 (pt) 2011-07-05
PL2418217T3 (pl) 2017-03-31
ES2388076T3 (es) 2012-10-08
IL189133A0 (en) 2008-08-07
JP2009507502A (ja) 2009-02-26
AU2006291541A1 (en) 2007-03-22
US20090305968A1 (en) 2009-12-10
KR101305533B1 (ko) 2013-09-06
AU2006291541B2 (en) 2012-04-12
CA2621337C (en) 2014-09-23
HK1163712A1 (zh) 2012-09-14
WO2007031280A2 (en) 2007-03-22
US20170320917A1 (en) 2017-11-09
RS52379B (en) 2012-12-31
HRP20160379T1 (hr) 2016-05-20
PL2418217T4 (pl) 2017-11-30
US20200062805A1 (en) 2020-02-27
CA2621337A1 (en) 2007-03-22
US20140200187A1 (en) 2014-07-17
JP5727393B2 (ja) 2015-06-03
BRPI0616824B1 (pt) 2020-10-27
NO20081664L (no) 2008-04-04
KR20080052586A (ko) 2008-06-11
ME02426B (me) 2016-09-20
ME02000B (me) 2015-05-20
SI1928903T1 (sl) 2012-09-28
PL1928903T3 (pl) 2012-10-31
CY1117351T1 (el) 2017-04-26
SI2418217T1 (sl) 2016-06-30
EP1928903B1 (en) 2012-05-30
DK1928903T3 (da) 2012-08-20
HUE029132T2 (en) 2017-02-28
EA014330B1 (ru) 2010-10-29
EP2418217A1 (en) 2012-02-15
NO342272B1 (no) 2018-04-30
US20160264630A1 (en) 2016-09-15
US8748395B2 (en) 2014-06-10
JP2012095657A (ja) 2012-05-24
UA98101C2 (ru) 2012-04-25
IL237984A0 (en) 2015-05-31
PT1928903E (pt) 2012-07-02
EP1928903A2 (en) 2008-06-11
RS54701B1 (en) 2016-08-31
US9290538B2 (en) 2016-03-22
EA200800680A1 (ru) 2008-12-30
ES2567708T3 (es) 2016-04-26
HRP20120598T1 (hr) 2012-08-31
EP3012266A1 (en) 2016-04-27
JP5386169B2 (ja) 2014-01-15

Similar Documents

Publication Publication Date Title
US20200062805A1 (en) Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
US8080517B2 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CA2387184C (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
EP1776958B9 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
AU2012203529B2 (en) Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05796243

Country of ref document: EP

Kind code of ref document: A1